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ABSTRACT 
 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity 
and mortality worldwide. It is mainly caused by long-term inhalation of smoke 
particles. 
 
AIMS 
This thesis aims to describe physical activity in COPD patients in the stable state, 
during exacerbation and subsequent recovery, and the factors which influence these 
phases especially those that are environmental. 
 
METHODS  
Physical capacity and activity was assessed with a variety of methods and devices.  I 
chose to use a six minute walking distance test and an accelerometer (SenseWear) 
device which estimates energy expenditure. A number of clinical factors were also 
assessed at the stable, exacerbation and recovery states through use of 
questionnaires (COPD assessment test, Hospital Anxiety and Depression Scale and 
Functional Assessment of Chronic Illness Therapy-Fatigue Scale). To prospectively 
collect data leading up to an exacerbation I used a pedometer which was validated 
against the SenseWear device and manual counting. Patients recorded their step 
counts on a total or 16,478 days- an average of 267 days per patient (range 29-658)-  
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when stable,  at exacerbation presentation (day 0) and at recovery visits (days 3, 7 
and 14 days thereafter). At the same time, patients recorded any increase over usual 
stable symptoms per day, time spent outdoors and Peak Expiratory Flow (PEF).  
 
RESULTS  
The 73 COPD patients (70% male) had a mean (±SD) age 71.1 (±8.7) years and 
FEV1 52.9 (16.5) % predicted. Results showed that daily step count in community 
treated exacerbations returns to pre-exacerbation levels within 3–4 days, with those 
patients experiencing the greatest reduction in step count taking longer to recover, 
and patients suffering frequent exacerbations experiencing a faster decline in 
activity. I also observed that patient activity in the stable state was inversely 
associated with high levels of atmospheric pollution.  Moreover patient activity was 
markedly lower during the weekends and during cold weather.  
 
At exacerbation, changes in exercise capacity, muscle strength and energy 
expenditure were related to disease severity, changes in the perception of fatigue 
and exacerbation frequency. The results also indicated that prior pulmonary 
rehabilitation may have a lasting benefit in mitigating this reduction in physical 
activity, and that possibly change in physical activity is associated with changes in 
systemic inflammatory markers at exacerbation. 
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CONCLUSIONS  
Maintenance of physical activity is important in COPD. Strategies that encourage 
activity when patients are unwell (such as personalised early Pulmonary 
rehapilation) or unwilling to take exercise (such as during the winter or weekends) 
need to be devised to prevent de-conditioning at these times. Physical activity and 
exercise capacity are reduced during COPD exacerbation recovery and may be 
linked to increased systemic inflammation and fatigue. Frequent exacerbators should 
be particularly targeted for exercise programs.  Schemes to reduce levels of 
atmospheric pollution should be further encouraged. 
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INTRODUCTION 
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This introduction describes the diagnosis of chronic obstructive pulmonary disease 
(COPD), its management and definition and the treatment of exacerbations.  
 
It also serves to review the current literature on physical activity and capacity, 
describing the relevant outcome measures, their implementation and limitations. The 
aims and objectives of the study are outlined.  
 
 
1.1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
COPD is a significant cause of morbidity and mortality globally. It describes the 
irreversible and progressive decline of lung function that leads to reduced airflow into 
the lungs. COPD contributes a significant burden of illness and generates high 
healthcare costs (7). Worldwide, COPD is ranked as the third greatest cause of 
death (8). COPD has been defined by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) committee as “a common preventable and treatable disease, 
characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases.  Exacerbations and comorbidities contribute to the 
overall severity in individual patients.” (www.goldcopd.org). 
 
 
There are two major components of COPD: chronic bronchitis and emphysema. 
Chronic bronchitis is defined as “the presence of cough and sputum production for at 
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least three months for two consecutive years” and emphysema is defined as 
“enlargement of the airspace and destruction of the alveoli” (9). COPD can be 
described as a long-latency illness in that it develops over a few years after initial 
causative agent exposure (10). Active smoking still remains a major risk factor 
although other factors are now being identified. These include air pollution and 
occupational factors (11). People exposed to these risk factors do not always 
develop COPD but may experience respiratory symptoms. These include chronic 
bronchitis and sub-clinical airway obstruction, and consequently the condition is 
difficult to identify during its early phases. Many people are not diagnosed until the 
later stages of the disease when breathlessness and impairment of daily activity 
cause them to seek medical advice (12). COPD speeds up the ageing process in the 
lungs. Therefore, the earlier individuals are treated and diagnosed, the more likely a 
positive outcome (13).  
 
1.2 EPIDEMIOLOGY 
 
In the UK, COPD is one of the leading causes of death and the second most 
common reason for emergency hospital admission. It is estimated to be responsible 
for almost 5 per cent of all fatalities and statistics show that approximately 3 million 
people in the UK have COPD (14). Estimates of its prevalence varies between 1 and 
4 percent of the UK populace, primarily affecting those over 35 years old (14).  
 
It is also the most expensive inpatient condition handled by the NHS (14). Over £800 
million is spent by the NHS on COPD each year. It is responsible for more than 24 
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million lost work days annually (14). COPD brings a considerable financial and 
societal cost, and as such warrants considerable research attention.  
 
Dyspnoea (breathlessness) is the principal symptom of COPD and presents the 
biggest challenge to patient welfare. This is normally a result of weakened 
pulmonary mechanics (10). Even after lung transplantation, exercise performance 
tends to remain substantially lower than that of age-matched controls. This raises the 
possibility that lungs alone are not responsible for breathlessness (15). Pulmonary 
function is interrelated with muscle strength. Muscle weakness, conversely, is a 
characteristic of COPD that plays a critical part in reducing a patient‟s exercise 
capacity (16). COPD dyspnoea occurs during exercise or even at rest in more 
severe cases (17). The cause of this dyspnoea is lung hyperinflation due to the early 
collapse of airways during expiration. This, in turn, is because the volume of 
surrounding tissue supporting the airway has been reduced following tissue 
destruction. Airflow limitation caused by blockage of the airways by mucus is also 
involved (18).  
 
1.3 AETIOLOGY 
 
The causes of COPD vary with respect to geographical areas. For instance, in high- 
and middle-income countries, tobacco smoking is the highest risk factor (19), but in 
low-income economies, exposure to indoor pollution such as biomass fuel used in 
cooking and heating is also an important cause of the disease (20). Other than 
smoke, COPD is associated with fumes and dust and exposure to certain forms of 
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dust and chemicals in the workplace such as grains, cadmium, coal, and 
isocyanates, which may lead to development of COPD even in non-smokers (20-22) 
(Figure 1). Air pollution also causes an abnormal inflammatory response, which may 
lead to parenchymal tissue destruction and loss of elastic recoil (emphysema) (23). 
 
 
 
Figure 1: Smoking cigarettes, biomass fuels, atmospheric pollution and occupational 
dust and chemicals cause healthy lungs to develop emphysema, with destruction of 
the alveoli and airways blocked with mucus. (Copyright ©ADAM.inc) 
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COPD develops at different rates in different people who are exposed to comparable 
amounts of similar pollutants (24).  Studies show that nitrosative and oxidative stress 
prompted by cigarette smoke contributes to the corticosteroid resistance found in 
COPD (1). According to Hansel and Barnes, oxidative stress might play a key factor 
in exacerbations by increasing the inflammatory response and might inhibit the anti-
inflammatory effects of corticosteroids, even at high doses (1). Genetic and 
epidemiologic evidence indicate that the ability of an individual to defend themselves 
against cigarette smoke-induced oxidative stress via up-regulation of the lung 
antioxidant defences is critical. This means that oxidative stress is an important 
event in COPD pathogenesis (25). Despite this understanding of the basic 
mechanisms involved in COPD there is no new or effective disease modifying 
therapy for this irreversible disease. 
 
1.4 PATHOPHYSIOLOGY 
 
Figure 2A shows features of emphysema and figure 2B shows the large thickening of 
the subepithelial basement membrane, hyperplasia of the subepithelial 
seromucinous glands, bronchial wall fibrosis, and goblet cell hyperplasia (chronic 
bronchitis) (26). This inflammatory damage overwhelms normal defence 
mechanisms and results in small-airway fibrosis and air trapping  
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Figure 2: Pathology of COPD.  A) Centrilobular emphysema. B) Chronic bronchitis 
(1). Copyright © 2009 Elsevier Ltd  
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Exposure to specific risk factors causes hypertrophy of mucous glands and mucus 
hypersecretion, which can lead to bacterial infection and cilial loss (27, 28). Similarly, 
exposure of the lung to noxious particles or gases stimulates an inflammatory 
response, whereby the lungs are infiltrated by neutrophils, macrophages and 
lymphocytes (9, 29). In COPD patients, destructive mediators and pro-inflammatory 
cytokines are released by immune cells, resulting in inflammation (30). Chronic 
inflammation leads to permanent structural change in the airway, such as alveolar 
destruction and epithelial hyperplasia, which is considered the third component of a 
vicious cycle (31) 
 
Another important part of the vicious cycle is the systemic component which involves  
the priming of circulating inflammatory cells, tissue hypoxia, skeletal muscle 
dysfunction and weight loss (32). In particular, skeletal muscle dysfunction limits 
patient exercise capacity and activity, and leads to muscle malfunction (33). A 
number of pharmacological therapies (e.g. bronchodilators) (32), and non-
pharmacological therapies (e.g. pulmonary rehabilitation), play an important role in 
the treatment and breaking of the vicious cycle of COPD (6).                                                                                                         
 
1.5 DIAGNOSIS OF COPD 
 
COPD diagnosis is based on both patients‟ history of exposure to risk factors and the 
presence of airflow limitation. People with persistent cough and sputum production 
and a history of exposure to risk factors are usually tested for airflow limitation even 
in the absence of dyspnoea (4).  
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A diagnosis of COPD normally requires a history of smoking or particulate exposure 
as well as lower respiratory tract symptoms of breathlessness, cough, wheezing 
and/or sputum production. The diagnosis is confirmed by spirometric tests that 
measure the amount of forcibly exhaled air in the first second of exhalation (FEV1) 
and forced vital capacity (FVC). COPD is diagnosed as an FEV1/FVC ratio <0.70 and 
its severity is based on FEV1 as a percentage of the normal FEV1 in healthy people 
matched for gender, age, height and ethnicity. There are four grades of COPD 
severity as defined by the GOLD (Table 1) (34).   
 
  
FEV1/FVC 
 
FEV1 predicted  
 
Grade 1: Mild 
 
<0.70 
 
≥80% predicted 
Grade 2: Moderate  <0.70 50%≤FEV1<80% predicted 
Grade 3: Severe <0.70 30%≤FEV1<50% predicted 
Grade 4: Very severe  <0.70 <30% predicted 
Table 1: COPD severity grades 
 
Spirometry is essential for COPD diagnosis. The process is easily performed in a 
hospital setting or by formal pulmonary function testing (PFT) in laboratories. 
Measurement of the diffusing capacity for carbon monoxide (DLCO) is another test 
that assesses the ability of the lungs to exchange gases and is useful in the 
diagnose of emphysema where lung volumes may appear normal. DLCO can be 
measured by one of two methods; both of these methods utilise carbon monoxide. 
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They are known as the single-breath and breath-hold techniques (35). Lung volume 
and ventilation tests are also important for diagnosing and differentiating between 
obstructive and restrictive disease. These tests can also be used to assess response 
to therapy (e.g. bronchodilators) and assess air trapping in the lung (36). Pulmonary 
function tests also include metabolic measurements which help to assess patient 
nutritional management by indirectly estimating resting energy expenditure (REE) 
(37). 
 
A normal chest X-ray does not exclude the diagnosis of COPD. Typical radiological 
findings include hyperinflation, escalation in retrosternal airspace on the lateral view, 
tubular heart, parenchymal hyperlucencies, and flattening of the diaphragm (38). In 
addition, a chest X-ray could be beneficial in excluding other related conditions such 
as heart failure, lung fibrosis and bronchiectasis. Although chest-computed 
tomography (CT) is not usually recommended, high-resolution CT (HRCT) can be 
used to confirm the diagnosis or to exclude related conditions such as lung fibrosis 
and bronchiectasis, and also to diagnose emphysema (39). When surgical 
procedures such as lung volume reduction or bullectomy are considered, HRCT is a 
critical requirement. Arterial blood gas analysis can offer the most convincing clues 
about the acuteness and severity of COPD exacerbation. In exercise tolerance 
testing, the ability of the patient‟s heart and lungs to provide oxygen and remove 
carbon dioxide is quantified (40).  
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1.6 CLINICAL MANAGEMENT OF STABLE COPD 
 
Management of stable COPD is characterised by a stepwise increase in treatment. 
This depends on disease severity. Health education plays a critical role in enhancing 
skills and ability to cope with COPD (34). The National Institute for Health and 
Clinical Excellence (NICE) has recommended strategies for managing COPD based 
on airflow limitation and symptom severity. Pharmacological therapy starts with 
inhaled therapy including bronchodilators, both short-acting and long-acting beta2 
agonists and muscarinic antagonists for relief of dyspnoea (41). As the disease 
worsens, additional therapy includes inhaled corticosteroids that have an anti-
inflammatory action. Oral therapy includes corticosteroids, theophylline, and 
mucolytic and antibiotic therapy (2). However, there is controversy over the benefits 
of inhaled corticosteroids. Non-pharmacological therapy includes smoking cessation, 
which is a crucial element in COPD management to prevent an accelerated loss of 
lung function (42). Pulmonary rehabilitation (PR) is also very beneficial and safe, as 
discussed further below. In the later stages of the disease, if required, the patient 
may be prescribed long-term oxygen therapy or nutritional supplements and those 
with upper lobe emphysema may undergo lung-volume reduction surgery (LVRS) 
(4). Lung transplantation, LVRS and bullectomy are considered only to treat patients 
with advanced stage of the disease and for patients are unresponsive to medical 
therapy (2).     
 
According to the NICE 2010 guidelines, there are several forms of inhaled 
combination therapy such as inhaled short-acting antimuscarinic antagonists (SAMA) 
(43). However, long-acting beta 2-agonists (LABAs) are the most effective first-line 
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bronchodilators in the management of stable COPD patients (Figure 3) (2). LABA 
therapy provides substantial benefits to patients such as improvement of symptoms 
and exacerbations; as it improves lung function, and reduces the frequency of 
exacerbations and the need for oral corticosteroid therapy (44). An added advantage 
of inhaled combination therapy is the possibility of one agent enhancing the function 
of the other (45). As COPD increases in severity, patients usually become 
hypoxaemic. In addition, some COPD patients could become transiently hypoxaemic 
after exercise and oxygen is used to enhance exercise capacity and to decrease 
disability (46). Oxygen can also be used to provide symptomatic relief in instances of 
breathlessness (47).  
 
Figure 3: COPD inhalation therapy (The National Institute for Health and Clinical 
Excellence, clinical guideline (2)). Inhaled Corticosteroid (ICS), Short Acting Beta 
Agonists (SABA), as inhaled Short-Acting Anti-Muscarinic antagonists (SAMA),  and 
Long-Acting Beta 2-Agonists (LABAs). 
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1.7 COPD EXACERBATIONS 
 
1.7.1 Definitions and Symptoms 
  
Exacerbations of the respiratory symptoms that require medical intervention are 
critical clinical events in COPD (48). Most exacerbations are due to infections but 
pollution may also play a role. However, over a third of severe exacerbations have 
no known cause (4).  
 
There is no generally agreed definition for COPD exacerbations. COPD 
exacerbations have been defined by respiratory symptoms and medication 
prescription or by symptoms alone, and (in some studies) by hospital admission. A 
standard definition might help guide decisions to treat, and help in research/ clinical 
trial design. Burge and colleague suggested the definition should not imply aetiology 
and severity (49). However, some studies used this definitions for exacerbation “a 
worsening of respiratory symptoms, which required treatment with oral 
corticosteroids or antibiotics or both”(50). Rodrigues-Roisin et al defined 
exacerbations as “a sustained worsening of the patient‟s condition, from the stable 
state and beyond normal day-to-day variations, that is acute in onset and 
necessitates a change in regular medication in a patient with underlying COPD” (51). 
However, both of these definitions required healthcare access where treatment can 
be given. On other hand, other epidemiological, clinical and pharmacological studies 
have assessed change in respiratory symptoms and defined exacerbations as an 
“Increase for two consecutive days in respiratory symptoms, with at least one major 
symptom “dyspnoea, sputum purulence or sputum volume) plus another major or 
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minor symptom (wheeze, cold, sore throat, and cough” (52). (modiﬁed from 
Anthonisen and coworkers, and used consistently in all London COPD cohort studies 
(53-56)). However, this requires daily symptom monitoring; therefore other 
interventional studies commonly define an exacerbation as health-care utilisation 
that typically involves the prescription of systemic therapy such as antibiotics and 
steroids, or hospitalisation (57). It is worth noting that exacerbation symptoms differ 
between individuals (58) and patients may also describe general malaise and fatigue 
which are non-specific symptoms of exacerbations.  
    
These episodes of worsening respiratory symptoms are common and lead to 
substantial morbidity and mortality (59). Exacerbations are also characterised by 
deterioration of physiological variables such as lung function (FEV1), peak expiratory 
flow rate (PEFR) and physical activity (time outdoors) (3).  
 
 
COPD patients with severe exacerbations are markedly inactive during and after 
hospitalisation (60) and skeletal muscle weakness has been associated with an 
exacerbation compared with stable COPD patients and healthy people (61). Efforts 
to enhance physical activity should be among the aims of disease management 
during and following a COPD exacerbation to prevent complications of inactivity, 
such as skeletal muscle dysfunction and reductions in quality of life (61, 62). 
According to Donaldson and colleagues, patients experience a significant decline in 
the amount of time spent outdoors during exacerbations compared with pre-
exacerbation levels (3). They show the time course for 136 COPD patients during 51 
days, which was included the percentage of time spent outdoor, together with 
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changes in PEF. In addition, there was significantly reduced in outdoor time between 
baseline and onset exacerbation (p=0.021) and also reduced when comparing 
baseline with post exacerbation period (p=0.024) (Figure 4) (3).  
 
 
 
 
Figure 4: Percentage of patients going outside and changes in PEF rate. This figure 
illustrates the time course over exacerbations which show the percentage of patients 
going outdoors (white circles) and changes in PEF rate for the same patients (black 
circles). Exacerbation onset (Day 0) and baseline is considered to be the week from 
day -14 to -7 (3). 
 
40 
 
 
1.7.2 Exacerbation Aetiology 
 
Exacerbations of COPD are caused by intricate interactions between the patient, 
environmental pollution, viruses, and bacteria (Figure 5). These are thought to 
escalate the inflammatory problem, particularly in the lower airways. This 
overpowers host defensive anti-inflammatory mechanisms, resulting in tissue 
damage.   
 
According to published data, 50–70% of exacerbations are caused by respiratory 
infections (63), 10% are caused by environmental pollution, and approximately 30% 
have an unknown aetiology (64). The relationship between bacteria and COPD is 
well-recognised (65). In most cases, bacteria are isolated from the sputum of a 
stable patient, and from lower airway samples obtained with a protected brush. This 
has revealed that approximately one third of patients are colonised by bacteria at 
any given time (66). There are various mechanisms by which bacteria have been 
shown to mediate COPD symptoms. For example, strains of H influenzae, S 
pneumoniae, and P aeruginosa cause a hypersecretion of mucus in vitro. In addition, 
H influenzae and P aeruginosa inhibit the frequency of ciliary beating (67) .  
 
In a comparison of patients during stable COPD versus during exacerbations of 
COPD, it has shown that there is a significantly higher prevalence of the airway 
bacteria H influenzae, S pneumoniae and M catarrhalis in patients undergoing an 
exacerbation (57.7% vs 26.9% prevalence, p= 0.001) (55) . Furthermore, the study 
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also illustrated that in patients who had these airway bacteria at both stable and 
exacerbated states, there was a significant 20-fold increase in mean bacterial load at 
exacerbation (108.5 vs 107.2 colony forming units/ml; p= 0.011) (55). 
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Figure 5: Triggers (bacteria, viruses and pollutants) of COPD exacerbations with 
increased airway and systemic inflammation leading to increased exacerbation 
symptoms (4). 
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1.7.3. COPD Exacerbation Frequency Status 
 
Frequent COPD exacerbators are generally considered as those patients who have 
two or more exacerbations per year, whereas those who have under two 
exacerbations per year are termed infrequent exacerbators. Patients with more 
frequent exacerbations have poorer health-related quality of life (68) and higher 
mortality (69). Donaldson and colleagues showed that the percentage decline in 
FEV1 in patients with frequent exacerbations was 4.22 %/year compared to 3.59 
%/year in patients with infrequent exacerbations. Also, patients with infrequent 
exacerbations decline by 25.3 ml/year compared to frequent 46.1 (p<0.001) (Figure 
6) (5). In addition, frequent exacerbators (≥2.47 exacerbations per year) had a 
greater decline in time outdoors (4.2 minute/day as  recorded on diary cards) when 
compared to 1.2 minute/day infrequent exacerbators  (p=0.011) (3) 
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Figure 6: Changes in Forced Expiratory Volume in 1 second during 4 years. A black 
circle shows infrequent exacerbations and white circles show frequent 
exacerbations. For those with infrequent exacerbations, FEV1 dropped by 25.3 
ml/year, whereas there was a 46.1 ml/year drop in those with frequent exacerbations 
(p<0.001)(5).  
 
 
The heterogeneity of COPD exacerbations mirrors their reliance on a complicated 
spectrum of interrelated factors. Therefore, the vulnerability to exacerbations and the 
foundation of a frequent exacerbator is most likely to be multifactorial. Classifying the 
contributory factors, such as the airway microbiome, the background airway 
inflammation, and the patient‟s immunological responses, could offer potential 
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targets in the attempt to change a patient‟s exacerbation frequency phenotype (70, 
71). Airways of frequent exacerbators are more inflamed and are characterised by 
higher levels of interleukins (IL)-6 and (IL)-8 even when in a stable state (72). 
Furthermore, the trajectory of frequent exacerbators‟ inflammation has been 
demonstrated to be worse and with higher levels of plasma fibrinogen and IL-6, that 
increase most quickly over time. During the exacerbation recovery periods, these 
patients have increased sputum IL-6 and C-reactive protein serum (CRP) (73), which 
makes persistent post-exacerbation inflammation a more likely result of recurrent 
exacerbation.   
 
 
1.7.4. Clinical Management of Exacerbation 
 
Pharmacological management of a COPD exacerbation can include advice to 
increase use of salbutamol (a short-acting beta2 agonist) and/or prescription of oral 
corticosteroids and/or antibiotics if the sputum becomes purulent (2).  
 
Short-acting beta 2-agonists like salbutamol (albuterol) assist in opening narrowed 
airways (74). Long-acting bronchodilators can be used as well. They help in relieving 
airway constriction and help stop bronchospasm. Antibiotics are often administered 
when an infection of the lungs is recognised (74). Expectorants, on the other hand, 
are used to assist in loosening and expelling mucus secretions. Oral steroids are 
often used to treat an exacerbation with high doses administered intravenously or 
orally(4). Typically, oral prednisone is used to treat exacerbations in the UK. In 
emergency treatment oxygen therapy is used (4, 75).   
46 
 
 
Clinical trials have not revealed a benefit for mechanical percussion (chest therapy), 
although one of them demonstrated a substantial fall in FEV1 (76). It is important to 
carry an initial hospital assessment in order to confirm diagnosis and to dismiss 
uncompensated respiratory acidosis (76). The use of mucolytics has been studied 
extensively; however, these treatments have been shown not to speed up FEV1 
recovery during exacerbation. It has been shown, however, that the use of 
mucolytics improves symptoms (77). Because frequent COPD exacerbations 
deteriorate a patient‟s health status, and may hasten failure in pulmonary function, 
treatment to diminish the frequency of the exacerbations is crucial (78).  
 
Non-pharmacological management of a COPD exacerbation includes patient 
education, such as checking for the correct use of spacer devices and inhaler 
technique. If hospitalised and in respiratory failure, the patient may need oxygen 
therapy, non-invasive mechanical ventilation if hypercapnic, and in the most serious 
cases invasive mechanical ventilation may be required (79). 
 
Pulmonary rehabilitation is not commonly considered part of COPD exacerbation 
management, although some studies have shown positive results of starting 
rehabilitation early post-exacerbation (80) as discussed further below. 
 
1.8 SYSTEMIC INFLAMMATORY RESPONSE IN COPD 
 
The pathogenesis of COPD has not been completely elucidated, although immuno-
pathological mechanisms with crucial roles for macrophages and neutrophils in the 
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mechanism of the development of the disease have been shown (81). The presence 
of inflammatory mediators and proteins such as IL-6, TNF-alpha, leptin, etc., have 
been shown in COPD (81), however, the absence of a correlation between the 
concentration of systemic and pulmonary cytokines necessitates further research to 
understand the exact mechanism of inflammation (82). Aging, hypoxia and 
hyperinflation due to smoking, pollution, etc., have shown to increase IL-6 and TNF-
alpha levels initiating systemic inflammation (82). The study of Hurst et al., (83)  
showed a positive correlation between upper and lower airway inflammation owing to 
the development of the postnasal drip and bacterial load in the nasal area shown by 
the presence of the neutrophil attractant IL-8 protein and colonization of bacteria in 
the lower airway, although the exact mechanism remains unknown (83). 
 
An easily measured systemic inflammatory marker is CRP. Previous studies in 
healthy people have shown significantly reduced CRP levels in exercising compared 
with non-exercising people (84-86). In COPD patients, CRP is raised and patients 
have impaired exercise performance and decreased daily activity (30, 87). CRP is 
one of the markers which has been shown to be increased in COPD patients 
compared with a healthy control group. As reported by a systematic review the mean 
difference between COPD patients and healthy people was 1.86mg/l (95% CI 0.75 to 
2.97 mg/l) (88).  
 
Several researchers have documented increased levels of neutrophil chemotactic 
factors in COPD patients. In sputum specimens, growth related oncogene-alpha 
(GRO-α) and monocyte chemoattractant protein (MCP)-1 have been shown to be 
significantly increased in patients with COPD when compared to healthy people 
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(smokers and non-smokers) (89). Recent studies have shown that levels of 
cytokines remain relatively high in COPD patients (90). In lung tissue and 
bronchoalveolar lavage specimens of COPD patients, high levels of chemotactic 
factors have been discovered suggesting that anti-chemotaxis agents could be a 
therapeutic strategy in the treatment of COPD. Various cytokines are responsible for 
the stimulation of leukocyte chemotaxis through interacting mechanisms. A 
developing theory concerning increased levels of cytokines in COPD states that 
these factors have direct roles in airway remodelling and in lung injury. A study using 
transgenic mice has shown interesting effects of cytokines in lungs. Interleukin 13 
(IL-13) was shown to escalate the expression of matrix metalloproteinases, which 
may change the lung‟s protease-antiprotease balance (91). 
 
 
Fibrinogen has been shown to increase in COPD patients compared with healthy 
individuals (92). It is a soluble plasma glycoprotein primarily produced in the liver and 
is converted by thrombin into fibrin during blood coagulation (93). Fibrinogen levels 
show a clear correlation with COPD mortality (94). The normal levels of fibrinogen in 
the blood are between 1.5 and 3.5 g/l (93), and the level increases during acute 
phases such as COPD exacerbation events, in response to raised IL-6 levels (95, 
96). 
 
1.9 AIR POLLUTION IN GENERAL AND SPECIFICALLY IN LONDON 
 
Air pollution may be summarized as the presence of various harmful substances, 
particulate and non-particulate matter in air from different sources, both outdoor and 
49 
 
indoor that hampers the health, welfare, and functioning of the biological entities of 
the environment, both plant and animal (97). The increasing quantities of harmful 
gases such as SO2, NO2, CO and others constitute the major pollutants that are 
released by the emissions of transport, industries, and domestic and commercial 
sources of fuel heating systems (97). The quality of air in developed countries 
including London has deteriorated immensely compared to rural environment owing 
the advancement of technology and development that has resulted in increasing 
levels of air pollution, with a considerable rise of fatal health conditions of the 
respiratory system such as COPD, lung cancer, etc., leading to increased number of 
death every year (98) making it necessary to adopt suitable measures to control 
emissions. 
 
Information concerning how the climate and atmospheric pollutants alter physical 
activity in COPD patients is particularly valuable for determining how physical activity 
might be encouraged. In particular, examining adherence to rehabilitation 
programmes would be beneficial.  
 
1.9.1 Effect of Air Pollution on Normal Subjects and COPD Patients 
 
Evidence shows that atmospheric pollution is a cause of COPD exacerbations (99). 
When pollutants come into direct contact with respiratory epithelium, they activate an 
inflammatory cascade, which causes damage to tissue. Different studies have 
documented the relationship between particulate matter such as ozone (O3), sulphur 
dioxide (SO2) and NO2 and respiratory inflammation (100, 101). COPD patients show 
greater sensitivity to air pollution particles than normal subjects. One study found 
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that the deposition of particles in the lungs evokes low-grade alveolar inflammation 
that results in COPD exacerbations (100). In a study by Gong and colleagues on the 
association between particulate matter (PM) and exposure and COPD 
exacerbations, a statistically significant fall in maximal mid-expiratory flow and 
saturation of arterial O2 were reported (102). The decrements were higher for normal 
subjects than for COPD patients. These disparate responses to air pollutants and 
increased sensitivity have several explanations, including the association between 
PM levels with other constituents of air pollution which could be responsible for the 
observed effects (103). Pollution episodes may also reduce activity as PM <10 
microns in diameter (PM10) in London increases symptoms of dyspnoea in COPD 
patients independently of other pollutants (104). PM10 and traffic density also reduce 
pulmonary function in COPD patients (105). In addition, traffic-related air pollution 
exposure has been shown to be positively associated with first hospital admission for 
COPD (106).   
 
1.10  PSYCHOMETRIC AND HEALTH STATUS IN COPD PATIENTS 
1.10.1 COPD Anxiety and Depression 
 
The Hospital Anxiety and Depression Scale (HADS) is a psychometric questionnaire 
with 14 items. This questionnaire reflects anxiety and depression in COPD patients; 
the minimum clinically important difference is 1.5, or a 20% change from baseline 
score (107). Van Ede and colleagues showed that the prevalence of depression 
ranges from 7% to 42% In COPD patients, and that this was four times greater than 
that found in healthy subjects. Also, the prevalence of anxiety was 15% when 
compared to a prevalence of 6% in healthy control subjects (p<0.001) (108, 109).  
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. 
1.10.2 COPD Health Status 
 
A COPD assessment test (CAT) and SGRQ questionnaire are used to assess health 
status in COPD patients.  
 
The SGRQ is a 50-item questionnaire with 76 weighted responses and has three 
component scores: activity, symptoms and impacts, as well as a total score. This 
scale is commonly used to assess health status in COPD patients. The 
questionnaire has been validated with activity measurements in COPD patients with 
tools and measurement values such as 6MWD, dyspnoea and FEV1 % predicted 
(110). The minimal clinically important difference in SGRQ has been estimated to be 
four units (111) 
 
The CAT is an eight-item questionnaire designed to assess patient health status and 
was developed for clinical use. The CAT questionnaire provides clinicians and 
patients with a simple and reliable measure of overall COPD-related health status for 
the assessment and long-term follow-up of individual patients. The CAT score rises 
by 5 units (12% of a 40 point scale, p>0.0001) from the stable state in COPD 
patients (n=229) to exacerbation (n=67) (112). Patients with infrequent 
exacerbations show a significantly lower score at baseline (24.1 ± 7.3) compared 
with those with frequent exacerbations (19.4 ± 6.8, p< 0.001) (54). The CAT 
questionnaire has been validations and shown to provide reproducible results. 
Furthermore, in the same study has been shown high correlation with SGRQ (r= 0.8) 
(112).  
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1.11  PULMONARY REHABILITATION 
 
1.11.1 Pulmonary Rehabilitation in Stable COPD 
 
Pulmonary rehabilitation (PR) is a hospital or community programme designed to 
help patients with chronic lung disease. The programme usually consists of physical 
exercise and an educational element. The exercise element comprises aerobic 
training of the lower limbs and may include upper limb exercise and strength building 
(113). The patient and their family or carer may also be informed of breathing 
strategies and receive psychological and nutritional counselling. The delivery of PR 
should involve a multi-disciplinary team including specialist physiotherapists, nurses, 
doctors, occupational therapists, psychologists and nutritionists (114, 115). 
 
PR should be considered for all COPD patients who have shown persistent 
symptoms or restricted activity and for those who are incapable of adjusting to the 
illness notwithstanding minimal medical management. The benefits of PR include 
improved functional exercise capacity, improved health status, reduced dyspnoea 
and a trend towards fewer hospital admissions and bed days (2) (Figure 7).  
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Figure 7: COPD vicious cycle of disabling symptoms. The cycle leads to worsening 
symptoms, physical inactivity, deconditioning, and exercise limitation(6). 
 
The benefits from PR can be attained irrespective of sex, age, smoking status or 
lung function (99). Recent evidence has shown that PR is associated with reduced 
healthcare costs (116). PR can be conducted in different structured programmes, 
which may have an impact on the level or the duration of long-term benefits (99).  
 
COPD patients can be referred by physicians to specialized pulmonary rehabilitation 
clinics to undergo a few weeks of physical training and education but poor uptake 
and a failure to continue exercising limits the effectiveness of this intervention. There 
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is a need therefore to understand the barriers to participation and sustained 
behaviour change (117). 
 
 
1.11.2 Pulmonary Rehabilitation Post-Exacerbation 
 
Most studies of PR in COPD have excluded patients with exacerbation due to 
concerns that early PR post-exacerbation may pose safety concerns (80). In 
addition, during exacerbation, increased muscle weakness (60) and persistent 
systemic inflammation may occur. These may confound the outcome measures 
normally used to assess PR such as exercise tolerance and quality of life (118). 
 
In the UK, one-third of COPD patients admitted to hospital are readmitted within 90 
days due to exacerbation (119). A PR programme delivered shortly after COPD 
exacerbation showed decreased re-admission rates in the following three months 
(120). Early post-exacerbation PR has also been shown to significantly improve 
exercise capacity, skeletal muscle strength, dyspnoea, quality of life and prevention 
of muscle atrophy (118, 119). However, Greening and colleagues showed that early 
PR during hospitalisation post-exacerbation did not improve patients‟ physical 
activity over 12 months post examination; also the same study showed that early PR 
did not reduce hospital re-admissions and mortality was higher in patients receiving 
early PR compared to usual treatment (121).  
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The time to start PR post-exacerbation has not been defined (116). Two studies 
which started PR within four to eight days of admission showed a reduction in the 
number of hospital admissions (87) and improved exercise capacity (122). Also, 
when PR was started within 10 days of hospital discharge there was improved 
exercise capacity and health status (123). Monitoring physical activity and exercise 
capacity post-exacerbation may help to identify the optimal time to start PR post-
exacerbation.  
 
Since PR programmes are focused on educating the patient to make lifestyle 
changes including increasing physical activity, seeking care at the earliest onset of 
exacerbation signs and quitting smoking, one advantage of PR following 
exacerbation of COPD could be associated with the readiness of the patient to 
change after an acute distress episode (116). Furthermore, COPD patients who 
participate in PR programmes receive continuity of care with regard to improving 
proper medication use and attention to crucial symptoms. However, attending PR 
programmes following acute exacerbation may be affected by severely reduced 
endurance, which necessitates slower exercise progression and a longer 
rehabilitation process (116). PR is ideal for patients who have persistent symptoms 
and a drop in functional status or health status. The improvement in health for COPD 
patients post-exacerbation is not necessarily associated with improvements in 
exercise tolerance (124). 
 
 
 
56 
 
1.11.3 Limitations of Previous Early PR Studies 
 
There are a number of limitations in previous studies examining early PR. As 
previously mentioned, rehabilitation was started on different days post-exacerbation 
onset (99). A number of studies did not show whether exacerbations had affected 
the outcomes they used to assess the benefit of PR (120, 123). Some studies relied 
on patient-reported outcomes and did not include an objective measure of physical 
activity such as accelerometry or pedometry. The results from previous studies may 
have been affected by recurrent exacerbations that follow from an index 
exacerbation and would have altered the schedule of PR (120). 
 
1.12  EXERCISING MUSCLE 
1.12.1 Regulation of Oxygen Delivery to Exercising Muscle 
 
Uptake of oxygen (O2) and the regional distribution of blood flow within exercising 
muscles are not homogeneous (125). However, it is evident that there is an increase 
of blood flow in active muscles relative to those that are not involved in the specific 
form of exercise. Even in muscle groups that are taking part in the exercise, the 
increase in blood flow is not uniform (125). These disparities in blood flow and O2 
distribution are associated with the composition of the muscle fibre type and the 
muscle tissue‟s recruitment patterns (126). Different studies have shown that the O2 
consumption rate is higher in the highly oxidative soleus muscle than in inactive 
muscles. There has been debate about the mechanism regulating O2 delivery to 
exercising muscles. There are those who favour the idea that the dynamics of VO2 
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adjustment during exercise are responsible whereas others suggest that overall O2 
delivery to muscle fibres is the limiting factor (127, 128). 
.  
1.12.2 Exercise Limitation in COPD: the Role of Peripheral Skeletal Muscle 
 
There is substantial peripheral skeletal muscle dysfunction in COPD patients (10, 
129), marked by an earlier onset of muscle exhaustion (post-exercise quadriceps 
strength lower than that pre-exercise) (129) and a reduction in quadriceps endurance 
(130).  Deconditioning or the presence of a specific myopathy may both play a role 
(10, 131), the latter perhaps driven by changes in the type of muscle fibre, reduced 
oxidative enzyme capacity and modified cellular bioenergetics, and reduced 
capillarity  (132).  
 
Recent studies have proposed other factors including exposure to systemic 
corticosteroids (133), systemic inflammation (134), hypoxia (135) malnutrition (136) 
and  cachexia (137) as possible causes of peripheral muscle disease. 
 
Cachexia is characterised by a loss of muscle tissue over fat, unresponsiveness to 
nutritional intervention (138, 139), along with increased protein breakdown (140). 
Loss of muscle mass in COPD patients is related to weaker peripheral muscles (10) 
and poorer quality of life (15) and increased mortality (141). The precise cause and 
the mechanism of cachexia in COPD are still unknown. However, evidence points to 
the involvement of pathological changes within intracellular mechanisms involved 
with the maintenance of muscle mass. Some of the potential factors that could 
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trigger these mechanism changes in COPD are myostatin, oxidative stress and 
inflammation (142). 
 
 
1.12.3 Exercise Training in COPD 
 
Exercise training is an important aspect of PR and enhances the exercise capacity 
(degree, maximal work and endurance) of COPD patients despite an irreversible 
aberration in lung function (143). Evidence has shown that exercise training 
enhances exercise tolerance for COPD patients over and above the benefits 
provided by maximising medical therapy (144). There are a number of factors 
attributable to exercise intolerance in COPD patients, with airway obstruction 
recognised as playing a major role in the impairment. A reduction in FEV1 on its own 
does not appear to cause a reduction in exercise capacity. This suggests that other 
factors are involved. Possible candidates could be pulmonary circulation 
abnormalities, reduced lung gas exchange, reduced performance of respiratory 
muscles, variations in the extent of hyperinflation, impaired right and left ventricular 
function, and decreased blood oxygen carrying capacity (145). In addition, skeletal 
muscle dysfunction, nutritional impairment and psychological factors could be 
involved (146). 
 
The type and intensity of training for COPD patients is the subject of debate. 
Although all types of training are likely to enhance exercise performance, various 
outcomes can be expected with respect to whether the patient is undergoing aerobic 
endurance or strength training, high or low intensity training, or upper limb and/or 
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respiratory muscle training (116). There is no single exercise programme which can 
be regarded as ideal for all patients. However, the exercise programme needs to be 
customised in order to meet the patient‟s goals with the resources available (147). 
 
There are a number of strategies that can be used to optimise the benefits of 
exercise training for specific COPD patients including supplemental O2 and non-
invasive assisted ventilation (148). In addition, nutritional support could be an 
essential additional intervention for improving exercise performance (149).  
 
In normal individuals, vigorous exercise causes the exercising muscle to develop 
contractile fatigue. This fatigue causes the force produced by the muscle for a 
particular neural input to decrease (131). However, when COPD patients exercise, 
they become breathless. This may cause them to stop exercising even before the 
exercising muscle can develop fatigue (150). On average, quadriceps muscle 
biopsies in COPD patients reveal a lower proportion of type I fibres and a higher 
proportion of type II fibres relative to normal individuals. Type I fibres are slow-twitch 
fibres which are characterised by slight tension and resistance to fatigue. On the 
other hand, type II fibres are fast-twitch, develop high tensions and are vulnerable to 
fatigue (151). 
 
 
1.13  PHYSICAL ACTIVITY 
 
Physical activity is defined as „any bodily movement produced by skeletal muscles 
that results in energy expenditure (EE)‟ (152). It is greater than that which is 
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expended at rest (maintaining body temperature and the function of the heart, lungs, 
nervous system and other body organs) (resting metabolic rate). Physical exercise is 
different from physical activity, which is defined as “any planned, structured and 
repetitive bodily movement” (152). 
 
In daily life, physical activity can be categorised as occupational, conditioning, 
household, sports or other activities. Physical fitness is defined as “The ability to 
carry out daily tasks with vigor and alertness, without undue fatigue and with ample 
energy to enjoy leisure-time pursuits and to meet unforeseen emergencies” (152). 
The amount of energy necessary to carry out an activity is quantified in kilojoules 
(KJ) or kilocalories (Kcal), but KJ is preferred over Kcal. Traditionally, Kcal has been 
used as a measure of heat. When stated as a rate, the quantity of energy used by an 
individual takes the form of a continuous variable (152). The total caloric expenditure 
that is associated with a physical activity can be determined from the amount of 
muscle mass which produces body movements and the duration, intensity and the 
frequency of muscle contractions (153).  
 
1.13.1 Physical Activity in COPD Patients 
 
Physical activity is important in the everyday life of the entire populace. Its intensity 
and amount are crucial because of its close correlation with health, and inverse 
correlation with loss of life and disability (154, 155). In the recent past, physical 
activity assessment has attracted much interest, especially in vulnerable populations 
like COPD patients. This group of patients require a lot of care and monitor closely to 
face this chronic illness. Maintenance of physical activity can substantially reduce 
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age-related mortality (156) but it is particularly important for patients with COPD 
since those who continue to exercise have less dyspnoea, fewer hospital admissions 
for COPD and reduced mortality. Growing concern about physical inactivity in COPD 
patients has led to global efforts to address the problem, as physical inactivity is a 
leading predictor of death in COPD (157). It is critical that patients are given 
personalised PR programmes of support and encouragement. Behavioural 
modification, as well as pharmacotherapy, is also an important step in assisting 
patients to lead more proactive lives (158). 
 
Physical activity has both physiological and psychological benefits particularly in 
reducing coronary heart disease and depression, which are more prevalent in COPD 
(159, 160). PR involving an exercise programme tailored to the individual is very 
successful at improving activity-related outcomes in COPD particularly after 
exacerbation (116) .  
 
 
1.13.2 Physical Activity in COPD Patients at Exacerbation 
 
Previous studies have shown that COPD patients are less active and less likely to go 
outside during exacerbations compared to a stable state  (3). Inactivity during 
hospitalised exacerbations leads to reduced walking and physical activity (60). There 
was also a significant reduction in quadriceps muscle strength during exacerbation 
after admission to hospital compared with stable COPD patients and healthy people 
(61). Physical activity has been assessed in hospitalised patients with an activity 
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monitor device (DynaPort, McRoberts BV, the Hague, the Netherlands) which 
patients wore for 12 hours on day 1 and day 7 of hospitalisation and after one month 
of discharge. This study showed that patients with exacerbations exhibited severely 
reduced physical activity during and after hospitalisation compared to one month 
after discharge (60).  
 
1.13.3. Assessment of Physical Activity  
 
Subjective methods are practical in that they offer patients the chance to gain 
insights into their performance in everyday functional and living activities. Specially 
designed diaries and questionnaires help to evaluate patients‟ perceptions on their 
capacity to undertake daily tasks. However, these self-reported surveys are not 
always accurate (155). Objective methods such as motion sensors on the other hand 
offer more reliable information. As a type of motions sensor, accelerometers detect 
body acceleration as a marker of movement and thus of energy expenditure (155). 
Pedometers also detect movement but tend to underestimate the amount of physical 
activity, especially during slow walking. Pedometers do not provide data on physical 
activity patterns or the time spent on various physical activities (161). 
 
The assessment and quantification of a patient‟s physical activities in daily life can 
be undertaken with one of the following methods: direct observation, physical activity 
questionnaires (self-report), diary card, quantification of EE and motion sensors 
(discussed below) (60).  
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These methods are characterised by a number of problems; for instance, direct 
observation is not only time-consuming but is also intrusive. Self-report 
questionnaires and diaries depend on memory, which makes them imprecise, 
particularly amongst the elderly, and they are time-consuming for participants (155). 
The radioisotope approach is an expensive methodology and is technologically 
complicated, e.g. it uses doubly labelled water or indirect calorimetry. Doubly 
labelled water is a non-invasive method which calculates as oxygen-18 is lost as 
H2O and CO2, and deuterium only as H2O. The difference in loss is thus an index of 
CO2 production, and thus energy expenditure (especially if respiratory exchange 
ratio/respiratory quotient are known). Indirect calorimetry assesses activity by 
measuring O2 consumption and CO2 production (162). Moreover, heart rate 
monitoring is both expensive and inexact for use with COPD patients who have a 
heart rate that varies due to medication and other causes unconnected with physical 
activity (163). 
 
Three important factors must be considered when one examines the accuracy and 
precision of any measuring method: validity, responsiveness, and reliability. A key 
aspect of validity is the method's reproducibility. However, reliability is a prerequisite 
for validity. Responsiveness refers to the measuring instrument‟s ability to identify 
change over time (164).  
 
1.12.3.1. Direct Observation 
 
This method records and counts patients‟ activities performed on videotape. It is an 
accurate technique for monitoring a patient‟s daily activity. The disadvantages of this 
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technique are that it is time-consuming, expensive, and demanding (155). It is also 
not feasible for a large number of patients because of the length of time required to 
investigate COPD exacerbations prospectively.  
 
1.13.3.2 Questionnaires 
 
Questionnaires are widely used to assess daily physical activity. This method has 
advantages in that it is inexpensive and suitable for use in large populations. The 
disadvantage of questionnaires is that they depend on the recall and accurate 
reporting of information by the patient. Differences in outcomes may be seen 
depending on the patient‟s characteristics, age, and culture (155).  
 
1.13.3.3. Diary Cards 
 
The diary card is a daily record sheet given to patients to record certain variables 
and is submitted or posted to the hospital clinic every month. This method can be 
used to assess patients over a long period; it is inexpensive and easily understood 
by patients. It also has disadvantages; for example, patients can underestimate or 
overestimate values, or inaccurately recall information, which could be an important 
limitation in older patients (155). 
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1.13.3.4. Activity Monitors 
 
Activity monitoring instruments are devices used to detect body movement and 
quantify physical activity over a period of time. Two types of these monitors are 
accelerometers (Energy Expenditure (EE)) and pedometers (steps).  
 
Energy Expenditure is widely used to assess physical activity. The gold-standard 
methods for measuring EE are doubly labelled water and indirect calorimetry, as 
explained previously. 
 
 
Accelerometers (energy expenditure)  
 
Accelerometer devices are considered a good way to monitor patient‟s physical 
activity. Accelerometers are electronic devices which can assess the intensity and 
quantity of body movement, level of physical activity, and EE based on body 
acceleration measurements (155). 
 
SenseWear Armband 7.0 
 
The SenseWear system comprises the system display device, SenseWear software 
and the SenseWear armband. The armband is utilised to monitor some diseases 
(metabolic disease), and help during diagnostic tests and studies such as nutritional 
diagnostics, cardiac and pulmonary studies, paediatrics, internal medicine and sleep 
screening (165, 166). Generally, it is used to monitor energy and caloric 
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consumption, physical activity and patient movement. This versatile monitor is worn 
by patients on the left triceps in a comfortable position such that it does not affect 
daily activities. The SenseWear system is utilised by researchers and clinicians and 
has been scientifically authenticated, featured in numerous peer-reviewed texts 
(165). SenseWear systems devices can be used to record and store data whilst the 
patient is away from the clinic. Hill et al used SenseWear and indirect calorimetry to 
determine average energy expenditure per minute for 26 COPD patients undertaking 
different tasks. They concluded that SenseWear was a useful device for estimating 
EE in patients with COPD who walk without a rollator (Figure 8) (165). The 
SenseWear device is a well-tolerated device in patients with COPD (165). It was 
found to make reproducible measurements and detect small but important changes 
(32, 165).  
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Figure 8: The energy expenditure (Metabolic Equivalents (MET)) measured every 
minute over all activities on day one of validation study (stable patients). Data 
comprise the mean and SD. Open circles: indirect calorimetry data; Closed circles: 
SenseWear armband (165). 
 
 
Many types of accelerometers have been used to assess physical activity. The 
SenseWear device is light and costs £5000 for one piece of software and five 
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armbands, i.e. approximately £1000 per armband. Other instruments are available, 
such as the RT3 (StayHealthy Inc., Monrovia, CA, USA) and DynaPort (McRoberts 
BV, the Hague, the Netherlands) accelerometers. There have been some issues with 
the RT3 in detecting non-human movements, such as registering bumpy car rides as 
physical activity (167). The DynaPort (McRoberts BV, the Hague, the Netherlands) 
accelerometer is one of the most accurate instruments, but is too large for patients 
and difficult to tolerate for days. In addition, each device costs £4900, which is 
considerably more than the SenseWear armband (155). 
 
 
Pedometer 
 
A pedometer counts each step a person takes by detecting the motion of the 
person‟s hips. The Yamax Digi-walker SW-200 uses a spring-suspended horizontal 
lever arm that moves up and down in response to the hip‟s vertical accelerations. 
This movement opens and closes an electrical circuit; the lever arm makes electrical 
contact and a step is registered. This pedometer has consistently been shown to be 
among the most accurate pedometers and is suitable for use by normal, overweight 
and moderately obese people (168). It has also been shown to be one of the most 
accurate step counters in a controlled laboratory setting (169). It is sufficiently 
inexpensive and thus can be used in a large cohort study and the model used in this 
study has been shown to be accurate within ±3% of the actual steps taken 95% of 
the time (170). Also, this pedometer has been tested on the 4.88-km pavement 
course and measured the number of steps to within 1% of the actual steps (171). 
This pedometer has been tested on different surfaces and showed in general that 
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the effect of walking surface (track versus sidewalk) on pedometer recordings was 
not significant. Lee and colleagues studied 43 individuals, who wore activity monitors 
whilst walking at different speeds on a treadmill. Steps counted by these devices 
were compared to the visual step count (Figure 9A and B). They concluded that the 
Yamax pedometer was both reliable and valid in measuring step count (Figure 9 C). 
There is one potential disadvantage in that it can underestimate the number of steps 
taken by people walking very slowly (2.0 mph (0.9 m·min-1)(171).  
 
Figure 9: Bland-Altman plots of agreement in step counted between the Yamax 
pedometer and visual step count during treadmill walking speeds of (A). 4.0 and (B). 
5.6 km.h-1. (C) Comparing daily activity monitors on treadmill walking at different 
speeds. 
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1.14  ESTIMATE EXERCISE CAPACITY AND MUSCLE STRENGTH IN 
COPD 
 
Exercise capacity is defined as the maximum amount of physical exertion that can 
be sustained by a patient (172). The measurement of exercise capacity demands 
that maximal exertion be prolonged in order to have a stable effect on both the 
circulation and the pattern of patient response (173, 174). The measurement of 
exercise capacity requires a complete and accurate history, which includes detailed 
and quantitative information concerning the intensity and duration of maximal effort 
and the features of the limiting symptoms.  
 
In an interview assessment, patients are requested to describe their observations 
relative to a recent period of physical activity. Laboratory measurements use a 
performance index where maximal exercise performance is characterised with 
respect to duration and intensity of effort. The resulting values and the associated 
limiting symptoms are then compared with historical estimates (175).  
 
The evaluation of muscle strength during rehabilitation could help identify muscle 
weakness and allow for targeted training programmes and mechanisms for 
monitoring progress. There are different techniques for measuring muscle strength in 
COPD. A dynamometer can be used to assess isometric, dynamic or isokinetic 
muscle strength, and can be applied to COPD patients (176). Both CT and magnetic 
resonance imaging (MRI) can be used to measure muscle mass (176). Other 
techniques can also asses s body composition- including assessment of skinfold 
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thickness, underwater weighing, and use of dual-energy x-ray absorptiometry 
(DEXA). 
 
1.14.1 Six-Minute Walking Distance 
 
The Six-Minute Walk Distance (6MWD) test was initially introduced to assess 
exercise tolerance in people with heart and respiratory problems (88). It is widely 
used to assess exercise capacity in patients with COPD. However, performing the 
test can be difficult for those patients who are severely physically impaired.  It can be 
used for measuring response to medical intervention in patients with severe to 
moderate lung and heart disease. It can also be used in conjunction with degree of 
obstruction (FEV1), the body mass index (BMI) and the dyspnea (MRC) scale to 
predict mortality (27). COPD patient mortality is evaluated not only by GOLD stages 
which is, based on the degree of obstruction (FEV1) (42), but also by using exercise 
capacity (6MWD), BMI and the dyspnea (MRC) scale to calculate the BODE index. 
The BODE index is a multidimensional grading system that predictor of the risk of 
death from respiratory causes. Celli and colleagues validated the BODE index within 
625 COPD patients and found that the BODE index it is better than FEV1 for in 
predicting that risk of mortality. This index is graded from low mortality risk to high 
mortality risk (0-10) (27). 
 
 
The 6MWD is a validated tool to follow progression and help determine outcomes. 
Walking fewer than 350m is associated with increased mortality, as reported in one 
study in the USA (177). However, patients who walk more than 350m in the 6MWD 
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have a relatively good prognosis and may not necessarily need to be followed or 
observed as closely, as reported in the USA, but this can change if warranted (177). 
The 6MWD minimal clinically important difference (MCID) is 26 ±2 metres (178). 
Also, MCID defined as “the smallest difference in score in the domain of interest that 
patients perceive as beneficial and that would mandate, in the absence of 
troublesome side effects and excessive costs, a change in the patient‟s 
management”(179) 
 
The American Thoracic Society (ATS) provides practical guidelines for the 6MWD 
(88). There is no practice test before the 6MWD, which is a particular advantage in 
COPD patients who are reluctant to take the test at exacerbation. In 2001, Solway 
and colleagues conducted a systematic review and compared the 6MWD, 2MWD, 
12MWD, the Self-Paced Walk Test and the Shuttle Walk Test. They found that the 
6MWD was better tolerated by patients, easier to administer, and more reflective of 
activities of daily living than the other tests (180). It was also correlated with the 
ability to perform sustained exercise such as walking (181). The disadvantage of a 
time- and self-limited test is that patients may tend to select a relatively comfortable 
speed and may not stress themselves by undertaking maximum effort (161) 
 
The 6MWD must be conducted indoors, where there is a flat, straight, long and 
enclosed hard surface hallway that is rarely travelled. Conclusively, the test is a 
suitable measure of functional capability for individuals with fairly severe impairment 
(88). 
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1.14.2. Quadriceps measurements (quadriceps maximal voluntary contraction 
force) 
 
Quadriceps muscle strength is a critical predictor of the functional abilities of a 
COPD patient. Assessment of muscle function entails the quantification of the force 
of maximum voluntary contraction. The contraction of the quadriceps muscle is 
measured with a muscle-testing chair called Cybex Norm dynamometer (Cybex, 
division of Lumex, Inc., Ronkonkoma, New York, USA) (182). The use of Cybex 
Norm has been shown to be effective in COPD patients. Magnetic stimulators can 
also be used to assess quadriceps force and fatigue. This is achieved by stimulating 
the nerve endings at the motor end plate region. When large pad electrodes are 
used, 30 to 50% of the whole muscle is activated and useful information is produced 
with minimal discomfort to the patient. However, the high costs of the measurement 
instruments are a major disadvantage of this technique (183).  
 
Baarends and colleague  shows that fat-free mass (FFM) significantly contributes to 
a disturbed peak exercise capacity in COPD patients (185). Tissue weakening is a 
key determinant of exercise capacity and health-related quality of life (HRQL) free of 
dyspnoea. Early research studies on quadriceps tissues have shown a reduced 
proportion of type I fibers and an increase in the proportion of type II fibers as 
compared to control group (normal individuals)(186-189). Consequently, Muscles 
myopathy is considered a feature of COPD. Histological examination of biopsy 
tissues taken from quadriceps shows a reduction in oxidative enzymes (190) and 
change to fatigable type II fibers.  So this leads to anaerobic metabolism at lower 
work rate than in normal people (184). Lactic acid produced by anaerobic 
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metabolism is then buffered by bicarbonate to yield CO2  (191).  In addition, two 
studies showed that C-X-C motif ligand 1 (CXCL1) levels were inversely correlated 
with quadriceps strength during exacerbation recovery visits in a hospital (61, 191). 
Decramer and colleagues have shown the consequences of corticosteroid use in 
COPD patients and related it to steroid myopathy (133, 192). 
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2 
HYPOTHESIS AND AIMS 
 
 
This thesis tests the hypothesis that physical activity is reduced 
during COPD exacerbation recovery, and that a number of other 
factors, especially environmental and inflammatory factors, may 
affect physical activity in COPD. 
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2.1. The aims of this thesis 
 To evaluate prospectively daily step count in COPD patients with a simple 
pedometer, before and during the onset of an exacerbation. To evaluate 
recovery in physical activity post-exacerbation and its return to stable state. 
 
 To evaluate the longitudinal trend of daily activity in patients with a history of 
frequent and infrequent exacerbations. 
 
 To examine the effect of weather variables and air pollutants on daily step-
count and hours spent outdoors, peak expiratory flow, worsening dyspnoea 
and health-related quality of life of stable patients with moderate to severe 
COPD.  
 
 To investigate whether acute changes in physical capacity (6MWD, and 
quadriceps strength) and activity (energy expenditure and daily step-count) in 
naturally acquired, outpatient-treated exacerbations are associated with 
changes in systemic inflammatory markers and fatigue levels. To determine 
which falls in exercise capacity and physical activity at exacerbation are 
associated with disease severity, frequent exacerbations or prior pulmonary 
rehabilitation (PR) attendance. Such information could aid the choice and 
targeting of interventions. 
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 To determine whether step counts measured by a pedometer (Yamax Digi-
Walker SW-200) are correlated with other measures of physical activity and 
whether the device can be used to assess COPD patients.   
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3 
METHODS 
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3.1 LONDON COPD COHORT 
 
The London COPD cohort is a group of approximately 200  COPD patients under 
longitudinal observation at the Centre for Respiratory Medicine, University College 
London. This cohort was started in 1995 for the prospective investigation of COPD 
exacerbations. Patients complete daily diary cards, are seen in clinic every three 
months and annually undergo a comprehensive medical review when stable. 
Patients are also seen at the onset of exacerbation and 3, 7 and 14 days post-onset. 
Patients who withdraw or die are replaced on a rolling basis. This cohort was 
designed to study the aetiology and pathophysiology of COPD exacerbations. The 
criteria for inclusion of patients to this cohort include an FEV1/FVC <0.7; and FEV1% 
predicted ≤ less than 80%; plus, a history of respiratory symptoms and plausible 
causative factor, usually tobacco smoking. Patients are categorised as mild, 
moderate, severe or very severe according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification (34). 
 
Patients with other primary respiratory diseases or those who are unable to complete 
daily diary cards are excluded. For the studies described in this thesis, patients were 
also excluded if they used a walking support (cane or frame), were confined to a 
wheelchair or used ambulatory oxygen cylinders.  
 
Some patients had been recruited prior to the start of this study, and thus patient 
characteristics in the stable state were those recorded as close as possible to the 
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start of this doctoral work in 2011 either at annual reviews or, for replacement 
patients, at recruitment.  
 
At recruitment, age, gender, chronic respiratory symptoms (including cough, sputum 
production and nasal symptoms), smoking history, comorbidities and influenza 
vaccination were noted. Also, social and family histories were recorded, as were 
occupational history and number of people living in the patient's home. Every new 
recruit is asked to recall the number of courses of antibiotics and/or oral steroids 
which have been administered in the last year for the treatment of a COPD 
exacerbation.  
 
FEV1 and FVC were measured with a Vitalograph Gold Standard spirometer 
(Vitalograph Ltd, Maids Moreton, UK). Height and weight were measured with 
electronic scales and height stick. Patients were asked to perform the six-minute 
walking test and quadriceps muscle test. Patients also completed the Functional 
Assessment of Chronic Illness Therapy (FACIT-F), St George's Respiratory 
Questionnaire (SGRQ), Hospital Anxiety and Depression Scale (HADS), London 
Chest Activity of Daily Living (LCADL), and  COPD Assessment Test (CAT) 
(Appendix A).  
 
 
3.2 ETHICS 
 
The study was approved by the London-Hampstead Research Ethics Committee and 
all patients gave written informed consent (REC 09/H0720/8).  
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3.3 DAILY MONITORING 
 
Patients were monitored on a daily basis with a diary card (Figure 10). The diary 
card had space for a month of entries on a sheet of A4 paper; three to four months‟ 
worth of entries were given to each patient and collected at their three-monthly clinic 
visits. For this study, 73 patients were asked to wear a pedometer (Yamax Digi-
Walker SW-200) at the waist on the left-hand side (193, 194) and record their daily 
step-count on the diary cards. The characteristics of the 73 COPD patients are 
shown in Table 2. After recording daily Peak Expiratory flow and noting respiratory 
symptoms, the patients were instructed to record on the diary card their estimate of 
the time that you were out of your own home on the previous day. 
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73 COPD 
patients  
 
Remaining 126 
COPD patients in 
the Cohort 
  
P-value 
Mean (±SD) Mean (±SD)  
Age  (years) 71.1  (±8.7) 70.2 (±8.8) 0.51 
FEV1  (l) 1.31  (±0.5) 1.40 (±0.5) 0.25 
FEV1 (% predicted) 52.9  (±16.5) 56.2 (±16.1) 0.22 
FVC  (l) 2.79  (±0.9) 2.76 (±0.9) 0.83 
FEV1/FVC (%) 47.8  (±12.6) 50.7 (±12.3) 0.11 
BMI (kg/m2) 26.8  (±5.6) 27.0 (±5.1)  
  
 
Median  ( IQR) 
 
Median 
 
(IQR) 
 
 
Exacerbations/year 2  (1.0-3.0) 
 
1.4 
 
(0.7-3.0) 
 
0.40 
  
% 
 
   
 
Sex (Males) 69.9 
 
 
62.6 
  
0.36 
Chronic bronchitis 54.3 
 
54.5  0.98 
Smoking at-
recruitment 35.6 
 
 
32.0 
  
0.77 
 
Table 2: Characteristics of the 73 COPD patients in the study and 126 COPD 
patients in the cohort not recruited to the study. 
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Patients were educated to use diary cards at the recruitment visit and re-educated as 
needed when visiting the clinic. The diary cards also have instructions and contact 
numbers on the back of every card (Figure 11). On enrolment to the COPD cohort, 
the research team ask patients to report exacerbations and attend the clinic if 
possible at the exacerbation onset. 
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Figure 10: London COPD cohort diary card. Red circle shows the exacerbation 
event. The card includes daily peak flow, change in symptoms, changes in 
treatment, hours out of the home and number of steps.    
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Figure 11: Diary card instruction sheet.  
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3.4 EXACERBATIONS AND STABLE STATE 
 
An exacerbation was defined as an increase for two consecutive days in respiratory 
symptoms, with at least one major symptom (dyspnoea, sputum purulence or 
sputum volume) plus another major or minor symptom (wheeze, cold, sore throat, 
and cough).  Five consecutive symptom-free days were required before identification 
of the next exacerbation. Symptoms were disregarded in identification of 
exacerbation onset if recorded continuously in the preceding five days. If earlier diary 
card data was unavailable due to recent recruitment (n=3 patients) then the number 
of exacerbations was based on patient recall or hospital admission record data 
(195). Symptom counts were obtained by summing each increased respiratory 
symptom recorded on diary cards per day.  
 
Patients were considered to be stable (non-exacerbating) 30 days after the onset of 
an exacerbation and at least 14 days after ending treatment (oral corticosteroids 
and/antibiotics). 
 
 
3.4.1 Exacerbation Frequency 
 
Patients were divided into two groups based on the number of exacerbations in the 
12 months preceding the start of the study: If earlier diary card data were unavailable 
because of recent recruitment then the number of exacerbations was based on 
patient recall and from the letter received from patient‟s GP.  Those with two or more 
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exacerbations per year were called frequent exacerbators and those with no or one 
exacerbation per year were called infrequent exacerbators (5).  
 
For this research, data from patients who experienced multiple exacerbations were 
averaged to avoid bias through repeated measures. However, I analysed 
exacerbations as individual events when investigating whether the characteristics of 
exacerbations (respiratory symptoms, treatment, and change in step count) 
influenced fall in activity or recovery. 
 
 
3.5 MEASUREMENTS AT BASELINE AND EXACERBATION 
 
All questionnaires, 6MWD and blood samples were prospectively collected from 
patients at baseline (3-month intervals), from 2011 to September 2013. For this 
study, a non-exacerbation associated measurement, nearest in time to the start of 
the exacerbation was used as baseline result to compared to the exacerbation. 
These baseline measurements were generally collected either at an annual review or 
a recruitment visit. For chapter 7, some baseline data may have been collected a 
year prior to an exacerbation but it is not possible to predict when an exacerbation 
will occur and it was felt that repeated testing every 3 monthly would be too 
burdensome.  
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Changes at exacerbations in symptom count and hours spent outdoors were 
assessed by comparison of the average over a seven-day baseline period which 
started two weeks before onset with the average over a seven-day exacerbation 
period starting on the day of onset. Recovery in symptoms was determined as the 
day preceding two days with no recorded increased symptoms.  
 
Changes at exacerbations in daily step count, symptom count, PEF and hours spent 
outdoors were assessed by comparison of the average value over a seven-day 
baseline period which started two weeks before onset with the average value over a 
seven-day exacerbation period starting on the day of exacerbation onset. Recovery 
was determined as the day after exacerbation onset when a three-day moving 
average of a parameter matched or exceeded its baseline value. The baseline was 
determined as the average daily step count over a 7 day period which started 2 
weeks before the onset of the exacerbations. A moving average was used to avoid 
false early recoveries when step count or lung function improved for just a single day 
but then remained below baseline for a few more days (196). 
 
 
Patients were asked to call a 24-hour phone line to arrange an appointment if their 
symptoms deteriorated. Most patients were seen within two days of the onset of 
symptoms. Exacerbations were defined as a worsening of respiratory symptoms not 
treatment. Generally, patients who attend our clinic do not go to their GP for an 
exacerbation as we provide transport and speedy appointments and appropriate 
treatment. 
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The patients were seen in clinic before treatment (day 0) and on days 3, 7, and 14 
after treatment. This timing was chosen to capture both the early, rapid phase of 
recovery and include a measurement. We conducted the 6MWD at all visits except 
day 0; questionnaires were completed, blood was taken, and pulmonary function 
tests were performed at every visit. In addition, symptoms were assessed over a 
week, from three days before to three days after the date of the 6MWD.   
 
 
Quadriceps muscle test and 6MWD were not conducted on the day of reporting 
exacerbation to avoid any harm to patients on that day. Energy expenditure and daily 
steps were continuously assessed with an accelerometer and a pedometer for two 
weeks. Also, patients wore the SenseWear and pedometer for 14 days starting from 
day 0 on the left side of the body, from waking until they went to bed at night, taking 
them off before sleeping or having a shower. 
 
 
3.6 STUDY DESIGN 
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BASELINE
6MWD /SenseWear armband (SWA) /Pedometer 
Measuring Peripheral Muscle Strength   
CAT/ Diary Card /HADS/LCADL/SGRQ 
Lung Function Test / CRP
EXACERBATION ONSET
Instruct patient on use SWA + handling instruction sheet  
Patients wear the SWA and pedometers for 14 days from this day
Measuring Peripheral Muscle Strength  
CAT/ Diary Card/ HADS
Lung Function / CRP
Recovery visits (days 3, 7,14)
6MWD / SWA  / Pedometer 
Measuring Peripheral Muscle Strength 
CAT/ Diary Card /HADS
Lung Function /CRP 
Day  14
Downloading the activity data from SenseWear  
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3.7 QUESTIONNAIRES 
 
In this study, I decided to use five validated questionnaires: 1) LCADL, 2) SGRQ, 3) 
HADS, 4) CAT and 5) FACIT-Fatigue.  
 
3.7.1 London Chest Activity of Daily Living scale (LCADL) 
 
The LCADL investigates the level of disability induced by dyspnoea. The 
questionnaire asks about breathlessness associated with 15 common activities and 
is subdivided into four areas: self-care, domestic, physical and leisure activities. 
LCADL was used to assess COPD routine activity on a Likert scale of zero to five, 
with low scores reflecting low physical activity and high scores reflecting patients' 
ability to undertake daily activity (9). The maximum score was 75 points (Appendix 
A).  
 
3.7.2 St George’s Respiratory Questionnaire (SGRQ) 
 
The SGRQ is a questionnaire designed to assess health impairment in patients with 
COPD. It is a 50-item questionnaire with 76 weighted responses and has three 
component scores: activity, symptoms and impacts, as well as a total score. The 
maximum score is 100 points and high scores indicate poor health status (197)   
(Appendix A). The SGRQ score can be calculated per component and total score. 
The first step to calculate score is summed the weights for all positive responses 
items. Then, the second steps is deducted the weights for missed items from 
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maximum weight for each component or for the total score. Then calculate the 
SGRQ score for each component or total score by using this equation: 
 
 =100 X  Summed weights from positive items in that component (all components) 
                     Sum of weights for all items in that component (all components) 
The maximum possible weights for symptoms component are 662.5, activity is 
1209.1 and impacts is 2117.8 and total weight for all component is 3989.4 (197)  
 
3.7.3 Hospital Anxiety and Depression Scale (HADS) 
 
The HADS is a 14-item questionnaire divided into two domains. The response to 
each question is measured on a scale of zero to three. The maximum total score is 
21 points for anxiety and 21 points for depression. If the total score for both is less 
than or equal to seven it indicates normal levels, a score between 8 and 10 indicates 
borderline abnormal anxiety and depression, and a score from 11 to 21 is considered 
abnormal (15) (Appendix A).  
 
3.7.4 COPD Assessment Test 
 
The CAT is a valid questionnaire and includes eight items. The CAT score is 
designed to assess COPD patient health status. The response to each question is 
measured on a scale of zero to five and the maximum total score is 40 points. High 
scores indicate poor health status (54) (Appendix A).  
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3.7.5 Functional Assessment of Chronic Illness Therapy–Fatigue 
 
The FACIT-F is a fatigue scale and it has been validated with COPD  (198). This 
questionnaire contains 13 items which measure a patient's fatigue during daily 
activity. The FACIT-F is measured in four points: four indicates no fatigue at all and 
zero extreme fatigue, and the total score is 52, (Appendix A).   
 
 
 
3.8 BODE INDEX SCORES 
 
The BODE (Table 3) index score combines four important variables in one score. 
BODE refers to (B) body mass index; (O) the degree of airflow obstruction measured 
by FEV1 predicted; (D) dyspnoea assessed by (MRC) scale; and (E) exercise 
capacity (6MWD). The BODE index ranges from zero to 10. A higher score indicates 
a higher risk of death (27). 
 
 
 0 1 2 3 
FEV1% pred ≥65 50-64 36-49 ≤35 
6MWD (m) ≥350 250-349 150-249 ≤149 
MMRC 0-1 2 3 4 
BMI (kg.m-2) >21 ≤21   
 
Table 3: Scoring the BODE index (total BODE 0 to 10 based on patients results) 
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3.9 MEDICAL RESEARCH COUNCIL (MRC) 
 
The MRC dyspnoea score was used as a measure of the degree of perceived 
breathlessness which is associated with level of disability (199) Patients choose one 
of the 5 following statements which best describes them:   
 
 
 Grade 1, "I only get breathless with strenuous exercise" 
 Grade 2, "I get short of breath when hurrying on the level or up a slight hill" 
 Grade 3, "I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on 
the level" 
 Grade 4, "I stop for breath after walking 100 yards or after a few minutes on 
the level";  
 Grade 5, "I am too breathless to leave the house or am breathless when 
washing or dressing". 
 
 
3.10 TEMPERATURE AND POLLUTION DATA 
 
Daily data for atmospheric PM10 (particulate matter of 10 microns diameter) and 
Ozone (O3) were obtained for Bloomsbury Square, Central London from the Air 
Quality Information Archive database (http://www.airquality.co.uk). Data from the 
archive is reported as µg/m3. The conversion factor of ozone is 1 ppb = 1.9957 µg/m3 
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at 20oC and 1013 millibar atmospheric pressure.  In London, one monitoring was 
more centrally located (Hackney) but it did not record data on PM10.  
 
 
Climatic data were the average of hourly readings over 24 hours at London 
Heathrow Airport obtained from the British Atmospheric Data Centre 
(www.badc.nerc.ac.uk). A dry day was zero precipitation defined by means of a 
tilting siphon rain gauge that produces an autographic record of rainfall accumulation 
to an accuracy of 0.1mm. A sunny day was when sunlight for a minimum of 0.1 
hours was of such intensity that a Campbell-Stokes recorder would, after the rays 
were focused, scorch thick card. The patients lived on average 7.29 km (SD 4.72) 
from the Bloomsbury Square site. 
 
 
3.11 ACTIVITY MONITORS 
 
3.11.1 Pedometer  
 
A Yamax Digi-walker SW-200 pedometer was used to count the number of steps 
taken per day (Figure 12). Patients were instructed to wear the device on the left 
side of the body all the time, except when sleeping or showering. Pedometer 
placement was standardised by placing it on the belt or waistband, in the midline of 
the thigh, consistent with the manufacturer's recommendation and with studies 
conducted previously (193, 194). Patients recorded daily step counts on daily diary 
cards. This pedometer has been shown to measure steps accurately in free-living 
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individuals (194) and in normal and moderately obese patients (200) and has 
detected differences in physical activity of COPD patients from day to day.  
 
 
A pedometer counts each step a person takes by detecting the motion of the 
person‟s hips. The Yamax Digi-walker SW-200 uses a spring-suspended horizontal 
lever arm that moves up and down in response to the hip‟s vertical accelerations. 
This movement opens and closes an electrical circuit; the lever arm makes an 
electrical contact and a step is registered.  
 
Patients could not be supervised with the pedometer so data collected over the initial 
seven days were discarded to avoid any learning effects. Only patients who had 
recorded more than 35 days of pedometry data were included in this analysis. 
 
All hundred ninety-nine patients in our rolling cohort were considered for participation 
in this study. Twenty-four patients were not eligible as they used a walking support 
(cane or frame), were confined to a wheel chair or used ambulatory oxygen 
cylinders; 30 refused. I eventually provided pedometers to 145 patients. Data were 
successfully acquired from only seventy three patients (table 2) due to the following 
reasons a) Twenty one patients once issued refused to use the pedometer b) 
Nineteen  patients lost their pedometers  c) Twenty three patients recorded less than 
35 days of data whilst stable  and d) Nine pedometers broke (e.g. loss battery and 
disappear number from screen). Patients are lost to follow-up for a variety of reasons 
(other medical problems, re-location, reluctance to travel to far, and frailty of 
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themselves or illness of a partner). Whether the loss causes a systemic bias is 
unknown and difficult to assess 
 
 
Instructions for using the pedometer (in the back of diary card) 
 
-  Attach the pedometer to your belt, beltless slacks, skirts or training suit bottoms 
using the clip.  
-  To open the pedometer hold it upright; grasp the top of the clip with one hand. 
Use the other hand to push the projecting portion of the case body between the 
sides of the clip away from the clip, thus opening the case. 
-  After you have written down the number from the pedometer on this sheet, 
press the yellow button to reset the pedometer.   
 
 
Figure 12: Pedometer (YamaxDigi-Walker SW-200). 
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3.11.2 SenseWear armband  
 
The SenseWear device is a body monitor with multisensing capabilities, and it 
contains an accelerometer that detects motion and can count steps, as well as an 
electrical circuit to measure the electrical conductivity of the skin and an electronic 
thermometer to measure skin temperature (Figure 13).  Software and calibration of 
the device against calorimetry enables automated monitoring of energy expenditure 
and daily activity (201).  
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Figure 13: The data collected by SenseWear and computer software.  
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The patient wears the SenseWear on the left triceps, a position that is very 
comfortable and does not hinder usual life activities. This position allows constant 
recording of total energy expenditure (EE), EE above 2.5 METs and activity duration 
at various EE levels (sedentary, moderate, vigorous and very vigorous) per second 
(Figure 14). When fully charged, it can be used for up to seven days. Before 
distribution to new users, the armband is cleaned and disinfected.  
 
 
 
Figure 14: The SenseWear structures.  
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The SenseWear Instructions  
 
This instruction was given to the patients to remind them how to use the SenseWear 
at home. 
 
1- Be sure the upper arm is clean, dry and free of lotion/oil then slide the 
armband onto your left arm.  
2-  Adjust the strap so that it fits comfortably, and then secure the Velcro pull-tab. 
Ensure that the sensors on the underside of the armband maintain continuous 
contact with your skin and that the armband does not slide off your arm.  
3- Do not secure the strap too tightly. You should be able to place two fingers 
beneath the strap.  
4- Wait for the armband to automatically power on. This may take up to 10 
minutes. Activation is indicated by a series of audio tones. 
5- Wear it when you wake up until you go to bed. Please remove it before you 
have a shower or bath and do not wear it until your body is completely dry.     
6- Try to clean it at the end of the day to avoid irritation.  
7- If you regularly do exercises or any other activities (walking, running, jogging 
etc…) press the armband button before and after activities to highlight your 
activities in the software. 
8- Plug in the charger when you take it off, to charge overnight. 
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3.12 SIX-MINUTE WALKING DISTANCE 
 
The 6MWD test is a measure of functional capability for individuals with fairly severe 
impairment. This individualised test examines patients' submaximal functioning level. 
The majority of the participants in the test are unable to reach the maximum exercise 
level and are, therefore, allowed to rest and stop during the assessment.  
 
The test measures the total distance a subject is able to walk in six minutes under 
standardised conditions (88). The patients walked along a 30-metre track. They were 
instructed to walk as fast as possible and warned that they would get out of breath or 
become exhausted. They were permitted to slow down, stop or rest as necessary.  
At the beginning and end of the test, heart rate and oxygen saturation were recorded 
(Appendix B). The patients were also asked to assess their dyspnoea and fatigue at 
the start and end of the test using a Borg Scale (Table4).   
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SCALE 
 
SEVERITY 
 
0 
 
No Breathlessness At All 
 
  0.5 
 
Very Very Slight (Just Noticeable) 
 
1 
 
Very Slight 
 
2 
 
Slight Breathlessness 
 
3 
 
Moderate 
 
4 
 
Somewhat Severe 
 
5 
 
Severe Breathlessness 
 
6 
  
 
7 
 
Very Severe Breathlessness 
 
8 
  
 
9 
 
 
10 
 
Very Very Severe (Maximal) 
 
Table 4: Borg Scale used to assess fatigue and dyspnoea 
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An absolute contra-indication for the test was unstable angina or a myocardial 
Infarction during the previous month. The American Thoracic Society (ATS) provides 
practical guidelines for the 6MWD (88). There was no practice test for COPD 
patients reluctant to take the test at exacerbation and it was considered unlikely they 
would undertake both a practice walk and a test. The 6MWD was undertaken 
indoors along flat, straight, long and hard surface hospital corridors when few people 
were about (88). 
 
3.13 QUADRICEPS MAXIMAL VOLUNTARY CONTRACTION TEST 
 
Quadriceps maximal voluntary contraction (QMVC) was measured with the method 
described previously by Edwards (202). The equipment used to measure QMVC 
included a chair with a seatbelt, strain gauge (Strainstall, Cowes, UK), ankle strap 
and horizontal bar (Figure 15). Patients were excluded if they were experiencing any 
neuromuscular or musculoskeletal problems, which included: spinal problems, 
primary muscle disease, mononeuropathy or polyneuropathy, osteoarthritis co-
existent, neuromuscular junction, peripheral vascular disease and stroke affecting 
the legs.  
 
I assessed the patient‟s right leg but patients could choose to use their left leg if they 
wished. However, all subsequent tests on the same patient were performed on the 
same leg to ensure consistency and reproducibility (Appendix B). 
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Figure 15: Quadriceps maximal voluntary contraction test structures 
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3.13.1 Quadriceps maximal voluntary contraction test instructions  
 
The quads chair calibrated every time it was connected to the computer software 
(Figure 16A and 16B). Patients were seated in the chair with knee and hip flexion of 
90 degrees and a seatbelt secured across the hips. The strain gauge was connected 
to a horizontal bar on the back of the quads chair. An inextensible strap was placed 
around the ankle, which connected to the strain gauge on the back of the chair. The 
ankle strap was positioned perpendicular to both the ankle and strain gauge. 
Patients were asked to put their hands/arms on top of their thighs, and asked not to 
lift their buttocks off the chair or arch their back. Patients warmed up prior to any 
recordings with four contractions at about 50% of maximal effort and four at 
approximately 75% of maximal effort. During the test, patients received oral 
encouragement. Patients were then asked to contract their quadriceps and push 
against the strap for at least one second. Six separate readings of QMVC were 
made and the maximum reading recorded. Patients rested for at least 20 seconds 
between attempts (Figure 16B).  
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Figure 16:  A) The quadriceps chair calibration and analysis screen and B) Screen-
grab of quadriceps measurement screen 
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3.14 SERUM C-REACTIVE PROTEIN (CRP) AND FIBRINOGEN 
MEASUREMENTS 
 
When patients attended for a baseline, exacerbation onset or exacerbation recovery 
visits, venous blood was collected from an arm vein. These samples were sent 
directly to the Clinical Biochemistry Department at the Royal Free Hospital for CRP 
and fibrinogen measurement. 
 
Serum C-reactive protein was measured with a Modular Analytics E 170 Module 
(Roche, Burgess Hill, UK) and plasma fibrinogen by the Clauss method (IL ACL Top 
Coagulation Analyzer, Lexington, MA). 
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4 
QUANTIFYING 
PHYSICAL ACTIVITY 
VIA PEDOMETRY IN 
COPD PATIENTS 
 
This chapter explored whether step counts measured by a pedometer (Yamax Digi-
Walker SW-200) were sufficiently correlated with other measures of physical activity 
prospectively to allow the device to be used reliably in COPD patients. The data 
were presented at meeting of the British Thoracic Society (BTS) in 2012, as attached 
in Appendix C 
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4.1 INTRODUCTION 
 
Physical activity is important in everyday life for the entire populace. Its intensity and 
amount are crucial because of its close correlation with health, mortality, disability 
and physical activity intensity (154, 155).  
 
The instruments for determining the level of activity include self-report questionnaires 
and motion sensors such as accelerometers and pedometers. Self-reporting is 
subject to recall bias and may not produce accurate information. As such, it should 
be used with caution when assessing the intensity, duration and frequency of daily 
physical activity. This technique is mainly applicable for group estimates rather than 
individual estimates (155). 
 
More reliable and detailed individualised data on walking and other physical activities 
can be obtained using motion sensors (155). While the motion sensors produce 
accurate information on the body movement, they are ineffective in estimating the 
energy expenditure. A multi-sensor armband has dual functionality recording both 
the body movement and energy expenditure (140). 
 
An extensive literature exists on the assessment of exercise capacity using the 
6MWD test and incremental Shuttle Walk Tests. It remains unclear if improving 
exercise capacity translates into greater daily physical activity. Intuitively the latter 
may be more important for patients but its measurement is more difficult as patients 
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need to be monitored throughout the day. Pedometers are cheap and simple for the 
patient to use, but there are few data to support their use in COPD patients (155).  
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4.2 AIMS  
 
 
 To assess how steps counted by pedometer (Yamax Digi-Walker SW-200) 
corresponded to actual steps walked and steps counted by SenseWear 
armbands (SenseWear, BodyMedia, Pittsburgh, PA).  
 
 To evaluate the relationship of average steps for 28 days with exercise 
capacity, quadriceps muscles strength and disease severity  
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4.3 METHODS  
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Statistical Analysis 
 
Data were analysed with SPSS (IPM SPSS Statistics 21). Normally distributed data 
were expressed as mean and standard deviation (±SD) and skewed data as median 
and interquartile range (IQR). Comparisons were made by paired Student t test or 
Wilcoxon signed-rank test. Multiple linear regression models were used to analyses 
the relationship between number of steps against other variables such as FEV1% 
predicted, 6MWD and QMVC.  
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4.4 RESULTS  
 
In total, 73 patients were studied. They had moderate to very severe COPD (Table 
2). Between 8 April 2011 and 30 November 2012, the patients recorded diary card 
data and wore the pedometer.  
Actual steps were counted by step counters (Tally Counter Hand Held Clicker 4 Digit 
Chrome Palm Golf People Counting Club) (Figure 17). 
 
 
Figure 17: A) pedometer (Yamax Digi-walker SW-200). B) Step counters (Tally 
Counter Hand Held Clicker 4 Digit Chrome Palm Golf People Counting Club) 
 
Pedometer with actual steps during 6 minutes walking  
Twenty one stable COPD patients had a mean (±SD) age 70.3 (8.7) years and FEV1 
51.0% predicted (±14.1); male gender 67%. Those group characteristics did not 
differ from those of the cohort from which they were drawn. Figure 18 shows high 
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correlation between steps counted by pedometer (Yamax Digi-walker SW-200) and 
actual steps during 6 minutes walking distance [r=0.96; p<0.001].  
 
 
 
Figure 18: The relationship between steps counted by pedometer (Yamax Digi-
walker SW-200) and actual steps. 
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Pedometer validation with steps counted by SenseWear armband during 
6MWD  
Forty COPD patients completed the 6MWD and wore on their left hand side a 
SenseWear armband and a pedometer. There was a high relationship between 
number of steps counted by SenseWear and pedometer [r=0.90; p<0.001] 
(Figure19). 
  
 
Figure 19:  The relationship between steps counted by pedometer (Yamax Digi-
walker SW-200) and steps counted by SenseWear armband (SenseWear, 
BodyMedia, Pittsburgh, PA). 
118 
 
 
COPD GOLD stages  
Figure 20A shows that the average number of steps was significantly different between 
COPD patients with different GOLD stage disease. Mean steps for patients with 
moderate COPD were 4678 (SE 442) steps per day. This was significantly higher by 
1659 steps per day than the average 3204 (SE 410) steps per day [p=0.018] in severe 
patients. Furthermore, step count was significantly lower in very severe patients by 
2233 steps per day, which averaged 2590 (SE 395) steps per day compared to 
moderate COPD 4678 (SE 442) steps per day [p=0.002].  No statistically significant 
differences were seen between patients with severe and very severe disease. Figure 
20B depicts the relationship between disease severity and average steps counted for 
28 days [r=-0.302; p=0.009]. 
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Figure 20: A) average steps/day count for 28 days for 73 COPD patients. From left 
to right, average steps for 44 moderate COPD patients, 22 severe patients and 7 
very severe patients. B) Correlation between activity (pedometer steps/day) and 
FEV1% predicted. 
120 
 
Daily steps with 6MWD and quadriceps muscles 
Figure 21 shows that patients with greater 6MWD distance took on average a 
greater number of steps per day over the 28 days following the test [rho=-0.54; 
p<0.001].  
 
Figure 21: Scatterplot between 6MWD and number of steps       
 
Stronger quadriceps muscles were related to higher daily step counts [rho=0.44; 
p<0.001] (Figure 22). 
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Figure 22: Scatterplot between QMVC and number of steps.       
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4.5 DISCUSSIONS  
 
This chapter showed the accuracy of the pedometer against actual number of steps 
counted during the 6MWD. In the second part compared step number counted by 
pedometer against step number counted by the SenseWear armband during 6MWD. 
Both results suggest that the pedometer is an accurate device for assessing daily 
steps. The last section of the results showed that daily step counts measured by a 
pedometer over 28 days correlated well with objective tests of physical capacity, 
disease severity, and quadriceps muscle strength.  
 
Previous studies (for example, that of Pitta and colleagues) (60) have monitored 
patient activity for just one day every week during exacerbation recovery (for two 
weeks) and one day at baseline (60). Other studies have used clinic tests requiring 
personnel to assess physical capacity (6MWD, Shuttle Test) (203) or questionnaires 
to monitor patient activity (204). However, these methods are not suitable for 
objective monitoring patient activity on a daily basis during an exacerbation when 
activity levels may change rapidly as the patient recovers. According to weekly 
activity reports, in the general population both men and women tended to be more 
active in the summer than in the winter (205). However, the weather varies from one 
day to another and this may change activity on a daily basis. In addition, patients 
need to monitor their health closely in order to understand their daily activity and 
what could affect it. Further work is required to show how COPD patients spend their 
day, and to ascertain why some patients are more active than others. 
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Skeletal muscle dysfunction and wasting is an important extra-pulmonary 
manifestation of COPD, particularly in severe disease. Over time, muscle weakening 
affects a patient‟s exercise capacity and they may complain of breathlessness and 
fatigue with minimum activity.  
 
The pedometer used in the current studies has consistently been shown to be 
among the most accurate pedometers available and is suitable for use with normal, 
overweight and moderately obese people (168, 194). It has also been shown to be 
one of the most accurate step counters in a controlled laboratory setting (169).  The 
pedometer is relatively inexpensive to use in a large cohort study and the model 
used in this study has been shown to be accurate within ±3% of the actual steps 
taken 95% of the time (170).  Also, this pedometer has been tested on a 4.88-km 
sidewalk course and measured the number of steps to within 1% of the actual 
number of steps taken (171).  
 
Exercise capacity and physical activity can be assessed with walking tests or 
questionnaires, or with expensive accelerometer-based monitoring devices that 
require regular clinic visits to download data. However, these approaches are not 
well-suited to capturing activity prospectively during an exacerbation in a large 
observational cohort, as patients need to be monitored continuously over many 
months before attending clinic in order to capture the prodrome and early stages of 
these events. Some studies have also reported that pedometers underestimate step 
counts in people who walk very slowly (171), but I found strong correlations between 
the step counts with this pedometer and actual steps and steps counted by 
SenseWear during 6MWD for patients of different ages, speed level and disease 
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severity. The assessment of COPD daily activity is important because these data 
can provide insight into COPD patients' goals and motivation to improve their activity 
or stop daily activity getting worse. We suggest that using a pedometer could be the 
best way currently to assess activity at home or outdoors in a wide range of COPD 
patients (205). 
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4.6. CONCLUSIONS  
 
Daily step counts measured by a pedometer averaged over one month correlated 
well with objective tests of physical capacity disease severity, and quadriceps 
muscle strength. Pedometry is a simple, cheap method for quantifying daily physical 
activity in COPD patients over a long period of time and during exacerbations in a 
large observational cohort. 
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5 
DAILY ACTIVITY 
DURING STABILITY 
AND 
EXACERBATION OF 
COPD 
 
This chapter assesses the impact of exacerbation on COPD patient‟s daily steps. 
The data have been published in BMC Pulmonary Medicine (206), as attached in 
Appendix C and was previously presented at a meeting of European Respiratory 
Society (ERS) 2013. 
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5.1 INTRODUCTION 
 
 
COPD is a respiratory system disease that also causes skeletal muscle dysfunction 
and reduction in patient activity. Physical activities are all the body movements that 
are produced by skeletal muscles and are associated with energy consumption 
(207). The decline in physical activity seen in COPD patients is itself associated with 
worsening deterioration in lung functions, more frequent hospitalization, and 
increased mortality rates (60, 207). Physical activity limitation is not well 
documented. Therefore, it is important to study the relationship between inactivity 
and mortality in chronic conditions such as COPD (208).  
 
According to Singh & Morgan, levels of higher level physical activity (e.g. brisk 
walking) reduce sharply in COPD exacerbation but recovers rapidly afterwards (209). 
For example, the outcomes of the study by Pitta and colleague showed that time 
spent standing and walking reduced in the first and second weeks of hospitalisation 
(60). Additionally, the study participants reported that the amount of time they 
devoted to the above activities increased after one month. Therefore, dyspnea and 
fatigue during exacerbation can affect a patient‟s level of activity.  
 
Patients treated in the community for an exacerbation are not actively encouraged to 
maintain their physical activity during exacerbation recovery. Possibly, information is 
lacking concerning the extent that physical activity decreases during these non-
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hospitalized events. These data would be needed for determining the sample size 
required for a clinical trial of early PR in community treated exacerbations. 
 
It is also crucial to assess physical activity when examining the effect of exacerbation 
since baseline activities vary with time and season. However, accelerometers can be 
expensive and demand that the patient takes frequent trips to the clinic to download 
the data. Therefore, such devices are unsuitable for continuous use and for 
conditions that require capturing of relatively rare events like exacerbations. 
Pedometers are alternative devices, which are cheap and straightforward to use, but 
have not been certified for use in COPD patients.  
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5.2 AIMS 
 
 To prospectively evaluate daily step-count determined with a simple 
pedometer, before and during the onset and recovery of an exacerbation 
 
 To evaluated the longitudinal trend of daily activity in patients with a history of 
frequent and infrequent exacerbations.  
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5.3 METHODS 
 
Seventy-three COPD patients participated in this study. There were no significant 
differences in the patient characteristics between patients involved in this study and 
126 patients excluded for reasons mentioned in the main methods (table 2). The 
diagram below shows the study protocol.  
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Statistical Analysis 
 
Data were analysed with STATA 8.2 (Stata Corporation, College Station, TX) and 
PASW statistics V.21 (SPSS Inc.). Normally distributed data are reported as a mean 
and standard deviation (SD) or standard error of the mean (SEM) and skewed data 
reported with a median and inter quartile range (IQR). Comparisons were made by 
paired Student t test or Wilcoxon signed-rank test as appropriate. Stable mean daily 
step count and other patient characteristics were related with a Pearson correlation 
or Spearman rank correlation. Random effect linear regression models were used to 
assess annual decline in daily stable step count and whether the decline was faster 
in frequent than infrequent exacerbators. A stable step count was defined as outside 
a period starting 2 weeks before and ending 2 weeks after an exacerbation. Data 
from patients who experienced multiple exacerbations were averaged to avoid bias 
through repeated measures. However, I analysed exacerbations as individual events 
when investigating whether the characteristics of exacerbations (respiratory 
symptoms, treatment, change in step count) was associated with a fall in activity or 
recovery.  The level of significance was set at p<0.05. 
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5.4 RESULTS 
 
Patients recorded daily pedometry data for a minimum of 35 days with the initial 7 
days considered as training and discarded for the purposes of analysis. The study 
took place over 19 months between April 2011 and November 2012. Seventy-three 
COPD patients had moderate to very severe COPD (Table 2). 
 
Decline of daily step-count between patients with frequent and infrequent 
exacerbations 
Daily step-count was recorded in the stable state on 14,653 days (median 169 days 
per patient; IQR 113-285; range 29 - 488) and for 2508 days with exacerbation 
(median 21 days per patient; IQR 0-57; range 0-239). Separately, daily step-count 
fell in the 33 infrequent exacerbators by 338 steps/year [95% CI: -504 to -170] 
compared to 708 steps/year [95% CI: -867 to -549] in the 40 frequent exacerbators 
(both p<0.001) (Table 5). The annual decline in daily step-count was significantly 
faster in the frequent exacerbators (p=0.003; see figure 23).   
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40: frequent 
exacerbations   
 
 
33: infrequent 
exacerbations   
  
 
Mean (±SD) Mean (±SD)  
Age  (years) 71.1  (±8.7) 71.1 (±8.6)  
FEV1  (l) 1.30  (±0.5) 1.32 (±0.5)  
FEV1 (% predicted) 51.7  (±15.2) 54.3 (±18.1)  
FVC  (l) 2.78  (±0.9) 2.81 (±0.8)  
FEV1/FVC (%) 47.6  (±11.9) 48.0 (±13.5)  
BMI (kg/m2) 26.9  (±5.6) 26.5 (±5.5)  
  
 
Median  (IQR) 
 
Median 
 
(IQR) 
 
 
Exacerbations/year 3  (2.0-4.0) 
 
1 
 
(0.0-1.0) 
 
 
 
Sex (Males) 70.0 
 
 
69.7 
  
 
Smoking at recruitment 40.0 
 
30.3   
  
Table 5: Patient characteristics in both patients group (frequent and infrequent 
exacerbations) 
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Figure 23: Daily step-count of 33 infrequent (number of days with data=6878) and 
40 frequent (number of days with data=7775) exacerbators; predicted values 
obtained from the random effects, linear regression model (test of interaction, 
p=0.003). Time 0 corresponds to the start of the study. 
 
Time course of daily step-count at COPD exacerbation 
Thirty seven patients experienced 79 exacerbations and the characteristics of these 
patients are reported on table 6. The median time since the last exacerbation was 
85.5 days (IQR 42-193). The shortest interval was 15 days. There was no record of a 
preceding exacerbation for 7 exacerbations as these patients had been recently 
recruited. There were no significant differences in patient characteristics between 
these 37 patients and the 36 who did not experience an exacerbation except a 
higher FVC (L) table 6.  
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  Mean (±SD) 
 
Age  (years) 70.4 (±7.9) 
FEV1  (l) 1.4 (±0.5) 
FEV1  (% predicted) 52.1 (±15.7) 
FVC  (l) 3.0 (±0.8) 
FEV1/FVC (%) 46.2 (±13.3) 
BMI (kg/m2) 
27.3 (±6.0) 
 Median ( IQR) 
Exacerbations per year 3 (1-3) 
   
% 
 Sex (Males) 78.4 
 Smoking at recruitment 32.4 
 
Table 6: Characteristics of the 37 COPD patients in whom pedometry data were 
recorded during one or more exacerbation 
 
Table 7 shows that daily step-count, symptoms count rises and PEF fell significantly 
at exacerbation but not hours spent outdoors or whether the patient went out or not. 
Daily step-count took a median 3.5 (IQR 1-8) days to return to baseline levels (see 
figure 24A). Symptom count rose and took 11 (IQR 8-17) days to resolve (Figure 
24B) and PEF (Figure 24C) took a median 4 (0-15) days to return to normal. Hours 
spent outdoors per day returned to baseline levels within 1.4 (IQR 0.3-5.3) days 
136 
 
(Figure 24D). Step count recovered significantly earlier than did symptoms (p<0.001) 
but not PEF (p=0.33) or hours spent outdoors (p=0.18). 
 
  
Stable 
 
Exacerbation  
 
Difference 
 
p-value  
 
Daily step-counts (step/day) 
 
4154(±2586) 
 
3673(±2258) 
 
-480(±1408) 
 
 0.045 
Symptom count 0.4(±0.7) 2.4(±1.0) 1.9(±1.3) <0.001 
Peak Expiratory Flow (L/Min) 273 (±109) 266 (±108) -7(±13)  0.005 
Time outdoors (hours/day)  3.4 (±1.8) 3.2(±1.8) -0.1(±1.1)   0.51 
Percentage of days on which 
patient went outdoors (%) 
 
84.4 (24.2) 
 
79.6 (26.1) 
 
-4.8(±18) 
 
  0.13 
 
Table 7:  Comparison between baseline and first 7 days of exacerbation (mean+SD) 
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Figure 24: Time courses of daily step, symptoms, peak expiratory flow and time 
spent outside. These are mean of data on consecutive days from -14 to +14 days 
before and after 79 exacerbations.  
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The relationship between fall in daily steps and respiratory symptoms and 
activity recovery   
Prevalence of major symptoms during 79 exacerbations was reported as  83.5% for 
dyspnoea, 43.0% for sputum purulence and 67.1% for increased in sputum volume. 
Also minor symptoms were reported as 43.0% for cold, 49.4 for wheezing and 21.5% 
for sore throat and 54.4% for cough. There was no relationship between symptoms 
and fall in daily step count at exacerbation or recovery in steps count, with one 
exception: the fall in step count was related to the presence of sore throat (p=0.037). 
Those with the largest falls in daily step count took longer to recover to baseline 
(rho=-0.56; p<0.001, Figure 25). (p=0.037). 
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Figure 25: Change in daily steps between baseline and exacerbation against time to 
recovery to baseline; 79 exacerbations (p<0.001).  
 
Activity and treatment 
The 37 COPD patients (28 male) had 79 exacerbations. Twenty-two exacerbations 
were untreated and showed faster daily activity recovery (median 0 days (IQR 0-3)) 
than treated exacerbations (3 days (IQR 0 – 6)) (p=0.030). However, 57 
exacerbations were treated in the COPD clinic (11 antibiotics only; 7 oral 
corticosteroids only; 39 both antibiotics and oral steroids). Figure 26 shows that 
68.4% of treated exacerbations were associated with a fall in daily step count 
between baseline and exacerbation compared to only 40.9% for untreated 
exacerbations (p=0.025). 
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Figure 26: The percentage of treated and untreated exacerbations during which 
daily activity fell between baseline (average days -14 to -8) and exacerbation 
(average days 0 to 6). (A lower daily step count than the pre-exacerbation baseline 
step count). 
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5.5 DISCUSSION 
 
The objective of the current study was to examine the fall and recovery in daily 
walking activity for ambulatory patients (COPD) with non-hospitalized exacerbations. 
Daily step count reduced by 480 steps per day during each exacerbation, and took a 
median of 3.5 days for step count to recover to baseline levels. Also, the daily step 
count reduced faster in patients who had frequent exacerbations. Additionally, 
exacerbations linked with a fall in the daily step had a higher probability of patients 
attending clinic and they received treatment.  
 
Previous work on activity during exacerbation recovery has been mainly based on 
the study of hospitalised COPD patients. Pitta and colleagues saw improvements in 
time spent walking in hospital compared to one month after discharge, but they 
observed no difference between day 2 and day 7 (60). Borges and coworkers 
reported that daily step count examined using the tri-axial accelerometer increased 
from 602 step/day on the 2nd day of hospitalisation to 3,575 steps/day at one month 
post discharge (p<0.001) amongst 32 consecutively-studied patients (211). However, 
exacerbations leading to hospitalization may be associated with different behavioral 
responses than those managed in the community because hospitalized patients may 
rest in bed for lengthy periods and fail to maintain their normal activities. Additionally, 
such studies fail to collect data before the start of exacerbation.  
 
It is likely that severity of the severity of the respiratory symptoms during the later 
stages of recovery is not sufficient to inhibit activity. This was demonstrated by a 
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past study that examined 1465 exacerbations and reported that patients have a 
lower probability of moving out of their homes during exacerbation (3). A similar 
trend was observed in the current study, but it was not statistically significant 
because a low number of patients were reviewed. It was noted that the time spent 
walking indoors and outdoors was constant compared to baseline data. Therefore, it 
can be concluded that patients having exacerbation walked more slowly or used 
transport while they were outside their home. Accelerometers can be used to 
examine the nature and amount of exercise taken.  
 
I found that a larger reduction in daily step count during exacerbation was associated 
with an extended time before activity returned to normal. Previous studies have 
shown that pulmonary rehabilitation programs started initiated early post-
exacerbation show a benefit compared to usual care (87, 118, 122, 123, 214, 215) 
possibly by avoiding muscle deconditioning through inactivity during bed-rest (62). 
But Eaton and colleagues reported there being no substantial impact on acute care 
utilization, though it was considered feasible and safe. Treated exacerbations took 
more time to recover than untreated exacerbations. Additionally, it was unclear why 
patients report some exacerbations and not others. Further, about 50% of 
exacerbations are unreported as they found these exacerbations from patient‟s diary 
card (212, 213).  
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The outcomes of the current research study are that patients who experienced 
frequent exacerbations have twice as fast an annual decline in daily step-count than 
patients with infrequent exacerbations. Frequent exacerbations are associated with 
reduced FEV1 (5) and increased systemic and airway inflammation (3, 216) and a 
higher likelihood of suffering depression (160) and fatigue (217) with patients 
becoming housebound faster. The precise mechanism of activity decline is unclear 
but it is possible that prolonged recovery or non-recovery after an exacerbation may 
contribute to this decline. Also, fatigue, depression, and anxiety are linked to 
exacerbations and could limit activity. The above could be seen in patients having 
frequent exacerbations since they have relatively extended hospital admissions, but 
hospital admission was not incorporated into the research study.  
 
A notable strength of this research study is that it maintained daily examination of 
patients to get reference activity intensity before start of the exacerbation. Reference 
data gathered from exacerbation is not acceptable since the daily step count reduces 
with time and changes with the season (213). But the study failed to consider and 
incorporate mild patients, patients using walking supports, or ambulatory oxygen 
having GOLD stage 1 COPD. However, outcomes from the current study can be 
applied to the community nursed exacerbations and hence a larger of COPD 
patients in the community. 
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5.6 CONCLUSIONS 
 
Pedometers may be a useful way to prospectively monitor and quantify physical 
activity during COPD exacerbations. Physical activity reduces during exacerbations 
and recovers with 3-4 days post-exacerbation. Frequent COPD exacerbators have 
an accelerated decline in physical activity compared to infrequent exacerbators. 
Reduction in daily activity is greater in those who report exacerbations and seek 
additional therapy. Non-hospitalised COPD exacerbations are also associated with 
reduced activity.   
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6 
INFLUENCE OF 
WEATHER AND 
ATMOSPHERIC 
POLLUTION ON 
PHYSICAL ACTIVITY IN 
PATIENTS WITH COPD 
 
This chapter examines the association of climatic variables and air pollutants with 
daily step count and hours spent outdoors, peak expiratory flow, worsening 
dyspnoea and health-related quality of life. The data have been published in 
Respiratory Research Journal:13 June 2015, as attached in Appendix C (218). The 
data have also been presented at a meeting of the American Thoracic Societies 
2014 (appendix C),  
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6.1 INTRODUCTION 
There is growing evidence showing the effect of particulate air pollution on the 
increase in severity of respiratory diseases, as well as the increase in the number of 
deaths resulting from respiratory and cardiovascular diseases (100). This has led to 
the decision by the United Kingdom government to use the evidence of health issues 
related to air pollution to develop exposure limits of air pollution in relation to human 
health. Consequently, effective measures to mitigate the effects of air pollution my 
reducing exposure limits of air pollution while at the same time minimizing pollution 
levels (100, 219). The Committee on the Medical Aspects of Air Pollution (COMEAP) 
recommended in 2011 the establishment of air quality alert systems that assist in 
providing essential information that aids in advising the public to reduce exposure to 
air pollutants (220-222). As a result, the systems help in reducing adverse effects of 
air pollution while at the same time helping health service providers to develop 
systems that reduce symptoms associated with effects of air pollution. 
  
Increased air pollution levels have been linked to the increase in severity of COPD 
and its development. Studies have shown that increased air pollution recorded over 
the past years have been accompanied by increased emergency department 
attendances and hospital admissions (223). This is evident by the data collected in 
the 1950s and 1960s which demonstrated that exacerbation in symptoms associated 
with COPD rose as the pollution index increased over similar period (224). 
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It is, however, important to note that the results that have been collected vary 
depending on individuals. The differences have been attributed to the susceptibility 
of individuals to air pollution, as well as the type of pollution mixtures that vary 
depending on the regions affected with this environmental issue (224). Furthermore, 
air pollution has been linked to the increase in cases of COPD (106). Pollution may 
also reduce activity and previously reported that particulate matter <10 microns in 
diameter (PM10) in London increases symptoms of dyspnoea in COPD patients (104) 
and reduce pulmonary function  (105) . Research studies have shown air pollution 
leading to enhanced impairment of the function of lungs which in turn leads to 
increased establishment of clinical features associated with COPD (19). 
 
The interest in the perceived correlation between air pollution and COPD has led to 
need to assess physical activity in older people (156, 225). However, the effect of 
weather changes on physical activity of patients suffering from COPD has not been 
established. Air pollution has been found to be associated with reductions in the 
activity of patients with COPD, especially when particulate matter exceeds the 
diameter of 10 microns. This has been reported in London where patients suffering 
from COPD depicted reduction in pulmonary function (105), as well as enhanced 
symptoms of dyspnoea (104). Furthermore, it has been established that there is a 
positive correlation between traffic-associated air pollution and first admissions of 
patients suffering from COPD (106). It was explained in chapter five that there is a 
positive link between reduction in physical activity and increase in severity of COPD 
symptoms (226). I intend to discuss the data collected in patients who reported 
stability in their clinical functioning in this chapter.  
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6.2 AIMS 
 
To examine the effect of weather variables and air pollutants on daily step and hours 
spent outdoors, peak expiratory flow, worsening dyspnoea and health-related quality 
of life of stable patients with moderate to severe COPD  
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6.3. METHODS 
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Statistical methods 
Patient characteristics are summarised as appropriate by a mean and standard 
deviations or standard errors, or a median and inter-quartile ranges, or as a 
percentage. 
 
Unadjusted analysis 
 
Generalised estimating equations (GEE) were used to model the association of 
weather and pollution with daily step count, PEF, CAT scores (assuming their 
Gaussian distribution), time (hours) outdoors (as Poisson distributed: used to model 
the number of events occurring within a given time interval) or worsened dyspnoea 
(with a Bernoulli distribution: is discrete distribution with two possible outcomes; 
either success(n=1) or failure (n=0)) on days with temperatures 22.5 oC as average 
of hourly readings. It was an a priori decision that a cut-off would be necessary as 
relatively hot weather can reduce time spent outdoors (227). To identify the inflexion 
in the relationship between activity and temperature we plotted mean daily step 
count against temperature in 0.25 oC intervals. After inspection, a cut-off of 22.5 oC 
was chosen as daily step count was highest at this temperature and decreased with 
temperatures below or above 22.5 oC this average of hourly reading. The GEE 
models took into account variations between individuals and repeated measures 
within the same individual. Robust estimates of the variance were made and 
therefore it was not assumed that my estimate of the correlation structure as 
independent was correct.   
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Comparisons between daily step count of a sunny compared to a dull day, or a dry 
versus rainy day were made by paired t-test, after first obtaining the average for 
each patient under the various conditions.  
 
Analysis of variance (ANOVA) was used to determine the effect of day of the week 
on daily step count, hours outdoors, O3 and PM10. Post-hoc comparisons were made 
between Sunday and Saturday, and between Saturday and Friday.  
 
 
Adjusted analysis  
 
GEE regression models were used to assess the association of climate and pollution 
with daily step count and the other outcome measures. These models included a 
linear term to adjust for age related decline, sine and cosine terms with periods of 
12, 6 and 4 months to allow for seasonal changes, and a variable for day of week 
with Monday as the first day of the week. All models included daily temperature, wind 
speed, rainfall, hours of sunshine and day-length as independent variables. Only two 
important pollutants were examined (PM10 and O3) so as not to dilute effects with 
multiple atmospheric pollutants. Data were unlogged as the overall R-squared for 
daily step count against temperature was higher un-lagged than with 1 days lag. The 
analysis was repeated using data collected during weekdays only (Monday-Friday) 
and during weekends (Saturday and Sunday) since activity was markedly dissimilar 
in these periods. The analysis was also repeated with an auto-regressive term (the 
previous day value of the dependent variable) in the model to adjust for 
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autocorrelation in the dependent variable. I also repeated the analysis of daily step 
count and the pollutants with time outdoors included as an independent variable. 
 
 
Distance to pollution monitoring site. 
 
Distances to Bloomsbury Square were calculated by Pythagoras theorem using the 
Northings and Eastings (in metres) for the centre of each patient‟s post-code. 
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6.4 RESULTS 
 
The 73 COPD patients (51 male, 22 female) studied had moderate to very severe 
COPD (Table 2). The patients recorded daily step count on 16,478 days with an 
average per patient of 267 days (range 29-658). Of these, 3020 days were excluded, 
as exacerbations commenced either two weeks before or after.  
 
The patients lived on average 7.29 km (SD 4.72) from the Bloomsbury Square site. 
Of the 73 patients, 61 lived North of the site and 66 lived East.  
 
The stable state dataset consisted of an average of 225 days of pedometry readings 
per patient (SD 139; range 29-578); 459 days of PEFR readings per patient (SD 139; 
range 124-768); 463 days per patient of whether or not dyspnoea was worse than 
usual (SD 138; range 124-680) and 70 days with a CAT score per patient (SD 87; 
range 0-356). During the week, the mean of each patient‟s average time outside the 
home per day was 3.05 hours (SD 1.51; range 0.52 to 7.3 hours). Over the whole 
week, there was a strong relationship between the average number of steps per day 
and the average time spent outdoors (regression coefficient =671 steps per day per 
hour outdoors; intercept = 1804 steps per day; p=0.001; see figure 27). 
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Figure 27: Relationship between the average steps per day for each patient and the 
average hours spent outside the home during the whole week. 
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Unadjusted analysis 
Warmer weather was associated with increased daily step count (Figure 28).  A 1 oC rise in 
temperature increased the count by 43 steps per day per oC (95% CI 2.14 to 84.4; p=0.039). 
However, when the temperatures exceeded 22.5 oC, patient activity appeared to decrease 
and  steps per day fell by -891 per 1 oC rise (95% CI -1735 to -47; p=0.038).  
 
 
Figure 28: Relationship between daily step count and daily temperature; data are averaged 
in 1 oC intervals. 
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Physical activity was higher on days with sunshine or without rain (Figure 29). The mean of 
patient‟s average step count on sunny days was 3938 per day (SD 2447) compared to 3596 
per day (SD 2260) on overcast days (paired t-test; p<0.0010).  Similarly, on dry days the 
mean of each patient‟s average step count was 3999 per day (SD 2507) compared to 3771 
per day (SD 2349) on days with rain (p<0.0001). 
 
 
 
Figure 29: (A) Daily step count on overcast versus sunny days. (B) Daily step count on dry 
versus wet days. Data are means + standard errors of the average for each patient; p-values 
by paired t-test. 
 
The day of week effected both daily step count and hours outside. A post-hoc analysis of 
variance showed that daily step count was 434 steps per day lower on Sunday than Saturday 
(p<0.001) and 353 steps per day lower on Saturday than Friday (p<0.001). Similarly, time 
outdoors was 0.55 hours lower on a Sunday compared to Saturday (p<0.001) and by 0.09 
hours lower on Saturday compared to Friday (p<0.001) (Figure 30). 
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Figure 30: Daily step count and time outside during the week in COPD patients; data are  
means + standard errors for daily step count; median + inter-quartile range for hours outside; 
p-values from a post-hoc analysis of variance and wilcoxon rank-sum test respectively. 
 
Adjusted analysis 
Table 8 shows results from the GEE models with daily step count data recorded during either 
(a) the whole week and (b) over Monday to Friday (weekdays). Daily step count increased 
significantly with warmer, sunny weather and fell with wet weather. Over the whole week, 
higher O3 levels were associated with decreased activity (p=0.005) but not with PM10 
(p=0.112). Conversely, over just weekdays, PM10 was associated with reduced activity 
(p=0.018) but not O3 (p=0.239). There were no significant seasonal effects (sine and cosine 
terms) with temperature included in the model. With inclusion of an autoregressive term, over 
the whole week, rise in O3 was still associated with reduced daily step count (p=0.008) and 
rise in PM10 also significantly and independently associated with reduced daily step count 
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(p=0.047). Inclusion of time outdoors as an independent variable in the regression model, 
eliminated  the effect of O3 on daily step count over the whole week (regression coefficient = -
3.9; 95% CI -8.8 to 0.9; p=0.113) and similarly between step count and PM10 over weekdays 
only (regression coefficient = -4.4; 95% CI -10.4 to 1.5; p=0.147). 
 
  
Over full week 
  
Weekdays only 
  
Regression 
Coefficient 
 
95% CI 
 
p-value 
  
Regression 
Coefficient 
 
95% CI 
 
p-value 
 
Temperature (oC) 
 
37.7 
 
14.1 to 61.4 
 
0.002 
  
36.5  
 
9.6 to 63.4 
 
0.008 
Sunshine (% day) 4.7 2.8 to 6.7 <0.001  4.0 1.8 to 6.2 <0.001 
Rainfall (mm) -16.8 -27.1 to -6.6 0.001  -15.3 -26.4 to -4.2 0.007 
Wind speed (m/s) -17.2 -37.6 to 3.2 0.099  -43.8 -66.2 to -21.5 <0.001 
PM10 (μg/m
3) -5.4 -12.2 to 1.3 0.112  -7.8 -14.2 to -1.3 0.018 
O3 (μg/m
3) -8.0 -13.5 to -2.4 0.005  -3.5 -9.4 to 2.4 0.239 
 
Table 8: Relationship between daily step count and environmental factors (climate, pollutants 
and weekday) over the full week, and during weekdays only; allowance was made for season, 
linear trend and day-length (data for these variables not shown). 
Table 9 shows only the effects of the two pollutants (PM10 and O3) on the various outcome 
measures over the whole week; weekdays and over the weekend. 
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Table 9: Relationship between pollutants (PM10 and O3) and daily steps count, hours spent 
outdoors, health status (CAT score), PEFR, dyspnoea, over the whole week; weekdays 
and the weekend; with allowance for season, linear trend, day-length, temperature, 
sunshine, rain and wind. 
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Time spent outdoors fell with higher O3 levels (p<0.001) for data collected over the whole 
week, just weekdays (p=0.001) and at weekends (p<0.001). PM10 show no effects on time 
spent outdoors on either whole week (p=0.275) or weekdays (p=0.217) or weekends 
(p=0.502). Dyspnoea increased and PEF fell with higher levels of O3 over the whole week 
(p=0.015 and p=0.054 respectively) and for weekdays only (p=0.017 and p=0.040 
respectively) but not at weekends. No effects of PM10 were observed on daily dyspnoea or 
PEF. No effects of either pollution were seen on daily CAT score.  
 
Figure 31 shows the residuals after fitting the climatic and other variables plotted against 
PM10 and O3. The plots show little effect of the pollutants on daily step count, time outdoors, 
PEFR and dyspnoea until they exceed around 60-70 μg/m3. CAT score appears unrelated 
throughout the range of pollutants.  
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Figure 31: Residuals from a GEE model that included temperature, wind speed, rainfall, 
hours of sunshine, day length, season and linear trend, plotted against daily PM10 and Ozone 
(O3) levels; data are averaged over 10 μg/m
3 intervals; bars as + standard error. 
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Figure 32 shows that O3 concentration was higher by 4.6 μg/m
3 (p=<0.001) and PM10 levels 
1.73 μg/m3 lower during the weekend but this increased in PM10 was not reached the 
significance level (p=0.057)  
 
 
 
 
Figure 32: PM10 and O3 concentrations during the week between 7
th April 2011 and 31 March 
2013 
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6.5. DISCUSSION 
 
In this chapter, the effect of atmospheric pollutants, meteorological factors, and day of the 
week factors on patients with COPD is discussed. The weekends were deliberately left out in 
the study as the physical activity of participants is not significantly affected due the fact that 
weekends are the period of rest. It was established that the participants would depict reduced 
activity during rainy, overcast, and cold days but would like to walk more during sunny, warm, 
and dry days. Previous studies have shown that healthy individuals tend to avoid engaging in 
physical activity during winter and colder seasons while, on the other hand, increasing their 
physical activity during sunny days (228). For instance, COPD patients have shown seasonal 
variation in their physical activity (229). However, in this study, I try to explore further the fact 
that patients tend to vary their physical activity depending on the meteorological conditions 
rather than the seasons as has been explained in previous studies.  
 
 
The findings which I discuss in this chapter takes into consideration the importance of 
incorporating the fact that COPD patients are forced to reduce their exercise as a result of the 
limitation of airflow caused by their conditions. Any further reductions of activity due to the 
weather or day-of-the-week may worsen muscular de-conditioning which is common in 
inactive COPD patients. Muscle weakness and feelings of frailty may make the patients feel 
unable to leave their homes and once this behaviour is established may prove difficult to 
reverse.  It might in part explain why health related quality of life is poorer in winter than 
spring or summer (230)  and measures of anxiety and depression higher in winter (231). 
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Additionally, the findings which I will discuss in this chapter are important because I am trying 
to show for the first time positive correlation between air pollution and physical activity which 
was made possible by carefully choosing participants with air-flow limitation, thus making it 
possible to easily determine effects of air pollution on their physical activity.  
 
At the highest levels, O3 was associated with reduced daily step count and time outdoors. 
The regression models which I used in the analysis showed that there was disappearance of 
the effects when the period that was spent outside was included in the study. For instance, 
when the number of steps/day was considered in relation to period spent outside, the 
dependent variable represented walking speeds when the adjustment of time was made.  It 
suggests that possibly air pollution influences the time spent outdoors but not walking speed 
when outside, however, as no direct measurements were made, this idea needs further 
investigation. 
 
My research findings suggest mechanisms by which outdoor atmospheric pollution may 
reduce outdoor physical activity. As shows previously by Tremblay et al which was 
determined that atmospheric pollution such as O3 that exceeded 200 ppb affected peak 
expiratory flow of elite cyclists during maximal exercise (232). However, this may lead to 
problems at low levels (233). Furthermore, I established that increased levels of O3 were 
associate with reduced PEF during weekdays (p=0.040). However, it was found out that the 
results were insignificant over the whole week (p=0.054). Kakinoki and colleague shows  that 
atmospheric pollutants led to harmful effects on airways, including airway ciliary activity 
reduction (234), inflammation of pulmonary system (235, 236), airway oxidative stress (237), 
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and enhanced bronchial reactivity (238). Additionally, blood pressure and heart rate were 
affected while there reports of mitochondrial damage when the patients are exposed to O3 
(239). It has, however, not been established that the patients were informed on the anatomic 
and systemic effects of atmospheric pollution. Additionally, increased O3 were positively 
correlated with increased dyspnoea. However, the relationship between higher O3 and CAT 
quality of life scores was not established in the study. The study did not determine the motive 
of patients avoiding to go out during higher levels of pollution. Limited evidence show that 
patients may be avoiding to go out when they get news alert from advisory systems regarding 
increased air pollutants (240). O3 is mainly emitted from motor vehicle exhaust fumes, and it 
is a colorless and odorless gas making it difficult to be detected (240).   
 
In London, a pollution haze can be seen on some days (241) but the patients might not live 
on hills or in high-rise buildings where these observations can easily be made. It has been 
found out that increased levels of O3 happen during hot weather when patients tend to avoid 
exercising. Based on this observation, it was prudent that I deliberately dismissed the data I 
collected when the mean temperature for the day and night exceed 22.5˚C, thus this was not 
included in my analysis. It is important that further studies are done to determine if and how 
COPD patients can detect increased atmospheric pollution. 
                                                                                                                                                                                                           
A number of limitations for this study have been noted. First, physical activity intensity was 
not determined. This was attributed to the fact that I was not able to use accelerometers 
which require weekly and bimonthly visits to hospitals to allow downloading of data. 
Consequently, this was not possible with the long-term study that I carried out. Secondly, 
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inaccuracy of pedometers, especially in patients with slow walking pace, has been reported. 
Thus, this would lead to a consistent bias in particular patients, and as a consequence 
patient‟s response to weather or pollution could not be easily established. Thirdly, the group 
was not able to comprehensively collect pedometry data as in the case of dyspnoea and PEF 
data. This is attributed to the failure of some patients to wear the allocated pedometer on 
particular days. Additionally, I do not know whether patients are currently in employment or 
participating in full-time voluntary work. Also, there were instances of the loss and breakage 
of pedometers during washing. Such challenges were difficult to address as replacement was 
only possible during clinic visits which was required after three months. Fourthly, a number of 
patients were excluded from the study when periods of exacerbation were not factored in the 
study leading to negligible data. Such patients exhibited frequent exacerbations, and their 
collected data was not included in the study. Fifthly, adverse weather conditions like ice and 
snow on the ground which might limit excursions outdoors by patients so as to avoid risks of 
slipping were not considered. Neither was there any consideration as to wind-chill effects as 
clothing and exposure to wind was unknown. Sixthly, it was not possible to assess pollution 
exposure of each individual forcing us to use the data collected Bloomsbury monitoring site 
and make the assumption that the data related to the exposure experienced by each patient. 
This assumption may not be valid and patients may experience greater or less pollution 
exposure. Seventhly, the definition of a rainy day could have included both day time and 
night-time rainfall. Night-time rainfall may have had less influence on patient‟s activity as they 
would be unlikely to go outside at this time even if the weather had been good. Lastly, 
difficulty to define a time period over which the influence of rain and sun should be assessed 
that would not be open to criticism. It is quite likely that 6 minutes does not constitute what the 
average person would consider sunny. Also, I defined a sunny day as the minimum 
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measurable unit of sunshine but such an unlikely that such a brief period would influence 
outdoor activity 
 
Previous research findings have shown that the data that was collected at the Bloomsbury 
site were well correlated with the pollution levels experienced at suburban sites (242), as well 
as in other regions of London (243).  However, collected outcome data for each participant as 
the semi-individual design which I employed has been validated to be used in air pollution 
studies (244). I deliberately analyze weekends and weekdays data separately and the data 
for the whole week. This was to avoid analyzing data for the day-of-the-week which could 
have been large, and thus confounding the results. It has been found out that O3 are higher 
during the weekends in most countries (245-247). On the other hand, PM10 is higher during 
weekdays (245). This was clearly depicted in London, and the considerations of these factors 
in my analysis assisted in reducing statistical power. As a consequence, the failure to report 
consistent effects during weekends and weekdays could be attributed to this development.  
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6.6. CONCLUSIONS 
 
The study findings that I have discussed in this chapter have far reaching implications. First, 
the findings could help healthcare providers to inform COPD patients to embrace physical 
activity as this is a basis for pulmonary rehabilitation which would in turn make patients to be 
tolerant, enhance quality of life, and mitigate breathlessness effects. Secondly, providers 
would be able to use the findings to develop rehabilitation policies that would be implemented 
during cold weather to reduce inactivity which has been found to be elevated during cold 
conditions. Thirdly, patients should be encouraged to perform exercises during the weekends 
as the findings show that COPD patients tend to take less physical activity during such days. 
Lastly, it has been established that higher levels of atmospheric pollution are associated with 
differences in daily activity of COPD patients. Thus, it is imperative that public health bodies 
should be encouraged to come up with measures to curb atmospheric pollution. Further 
studies with personal pollution monitors are required to confirm these findings.  
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7 
DETERMINANTS OF THE 
REDUCTION IN 
PHYSICAL ACTIVITY AND 
CAPACITY WITH COPD 
EXACERBATIONS 
 
This chapter assesses the reduction in physical activity, capacity and muscles at COPD 
Exacerbations and related to inflammations level. Some of the findings of this study have 
been previously reported in abstract form (appendix C). The data will be published in 
European Respiratory Journal (ERJ):28 April 2016 (in press). 
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7.1 INTRODUCTION 
 
Muscle disuse is a common feature in COPD patients, and inactivity, chronic inflammation, 
hypoxia, coexisting heart disease, malnutrition, and use of corticosteroids are the most likely 
mechanisms involved in exercise intolerance (137). External factors, such as ageing and 
comorbidity, can hinder the ability to describe the association between lung weakness and 
changes in peripheral muscles in patients with COPD (248). 
 
The aetiology and natural history of limb muscle dysfunction is probably multifactorial with 
significant inter-individual variation. Deconditioning due to low habitual physical activity is 
thought to be the key driver of muscle dysfunction but other disease related factors such as 
systemic inflammation have been proposed as additional factors in some patients(249). 
Pulmonary inflammation and bacterial colonisation have been shown to be closely 
related,(250) but whether systemic inflammation, when present, is driven by pulmonary 
inflammation or bacterial colonisation is unknown.    
 
A reduction in skeletal muscle strength in patients at exacerbation of COPD has been 
demonstrated in several studies. For instance, Spruit and colleagues found a marked 
reduction of skeletal muscle strength in patients with exacerbation of COPD as compared to 
stable patients (60). They also found a significant reduction in quadricep muscle force after 
hospitalization that improved three months after the patients were discharged (60). Muscle 
weakness is multi-factorial and includes administration of steroids, and modification of 
metabolism, nutrition prolonged inflammation and high oxidative stress (61). The weakness of 
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muscles affects the capacity to exercise, reduces quality of life and increases mortality rate 
(251).  
  
Lacasse and colleagues showed that regular activity and exercise may be considered a 
therapeutic intervention with several benefits, for example defence against COPD 
(115). Skeletal muscles can be considered as an endocrine organ as cytokines and other 
peptides that are released from muscle fiber and they exert paprcrine autocrine or edocrine 
effects. These proteins are termed “myokines” (252). A well-known myokine is the gp130 
receptor cytokine interleukin-6. This marker increases up to 100 fold in the bloodstream after 
30 min of physical  exercise (252). There is an intriguing possibility that the IL-6 response 
may be a signal indicating that muscle glycogen stores are reaching critically low levels and 
that the active muscles' reliance on blood glucose as a source of energy is on the 
increase(253).  Patients who joined cardiac rehabilitation for three months have been shown 
to have a significant reduction in CRP (40%) when compared to a non-training group (19% 
reduction) (254). Also, the majority of studies suggest that activity and exercise programs are 
associated with a reduction in level of CRP (255).  
 
Skeletal muscle weakness has been shown to be an important predictor of exercise limitation 
in COPD (256).  Muscle weakness at exacerbation has been attributed to hypoxia inhibiting 
muscle protein synthesis and activating muscle protolysis, oxidative stress, up-regulation of 
apoptosis, enhanced systemic inflammation or result from treatment with oral corticosteroids 
(257). The inflammatory cytokine, interleukin-6 (IL-6) increases in both airway sputum and 
blood at exacerbation (72, 258). Infusion of IL-6 into rats causes skeletal muscle atrophy 
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(259, 260). No study has yet examined the relationship between systemic inflammatory 
markers and exercise capacity or physical activity during the very early phases of an 
exacerbation.  
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7.2 AIMS 
 
 To investigate whether acute changes in exercise capacity and quadriceps strength 
and physical activity (energy expenditure and daily step count) during naturally 
acquired, outpatient treated exacerbations are associated with changes in systemic 
inflammatory markers and fatigue levels. 
 
 To examine whether falls in exercise capacity and physical activity at exacerbation 
were associated with disease severity, frequent exacerbations or prior pulmonary 
rehabilitation attendance. Such information could aid the choice and targeting of 
interventions. 
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7.3 METHODS 
 
 
Protocol 1 
Fifty patients were asked to wear a SenseWear armband 7.0 (Bodymedia Inc, Pittsburgh, 
USA) over their left tricep continuously for 14 days from the day of reporting exacerbation to 
the clinic for except whilst washing or sleeping. The device measured indirectly energy 
expenditure and has been validated for use in COPD patients (140). Data collected on days 
with incomplete recording (day 0 and day 14) were excluded. Patients also undertook a 
6MWD test on days 3, 7 and 14. Due to changes in 6MWD over time, only data from patients 
with an exacerbation and baseline measured in the same 12 months period were analysed. 
See consort diagram 1. 
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Diagram 1 (protocol 1) 
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Protocol 2 
Forty-seven patients underwent QMVC testing on days 3, 7, 14 post exacerbations previously 
described by Edwards (202). The equipment used included a chair with seatbelt, strain 
gauge, ankle strap and horizontal bar. Data were collected during different exacerbations to 
those in protocol 1 but 19 patients undertook both protocols. Exacerbation and baseline data 
were collected in the same year.  See consort diagram 2.  
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Diagram 2 (protocol 2)  
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Statistical analysis 
 
All data were analysed with SPSS (IPM SPSS statistical 22). Normally distributed data are 
reported as a mean and standard deviation (SD) or standard error of the mean (SEM) and 
skewed data reported with a median and inter quartile range (IQR). Data recorded at baseline 
and during recovery were compared by paired Student t-test and Wilcoxon rank-sum test. 
The relationship between changes in 6MWD, QMVC, FACIT-F, and CRP between baseline 
and exacerbation were examined by Pearson correlation (r) or Spearman rank correlation 
(rho). Significant was taken as a p-value <0.05. 
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7.4 RESULTS 
 
Table 10 shows the characteristics of the 50 COPD patients who wore the SenseWear armband 
(Protocol 1) and a subset of 44 patients who agreed to a 6MWD test during exacerbation visits. 
Table 10 also describes the 47 patients whose QMVC was measured (Protocol 2).  
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Table 10: Characteristics of patients participating in protocol 1 and protocol 2  
 
  
 
SenseWear 
armband  
(50 patients)  
 
6MWD 
(44 patients) 
 
Quadriceps 
muscles test 
 (47 patients)  
 
Mean (±SD) 
 
Mean (±SD) 
 
Mean (±SD) 
 Age (years) 72.9 (±8.2) 
 
73.3 (±8.3) 
 
72.4 (±7.8 
 
FEV1  (% predicted) 50.7 (±15.1) 
 
50.9 (±15.8) 
 
50.1 (±17.2) 
 
FEV1  (l) 1.36 (±0.6) 
 
1.33 (±0.6) 
 
2.24 (±0.5) 
 
FVC  (l) 2.78(±0.9) 
 
2.71 (±0.9) 
 
2.81 (±1.0) 
 
FEV1/FVC (%) 48.8 (±13.2) 
 
49.2 (±13.6) 
 
45.2 (±13.6) 
 
BMI (kg/m2) 26.6 (±5.6) 
 
26.6 (±5.6) 
 
25.9 (±5.6) 
6MWD (meter) 414 (±111) 
 
414 (±111) 
 
426 (±104) 
  
 
Median (IQR) Median (IQR) Median (IQR) 
 
Exacerbations/year 2  (1.0-4.0) 
 
2(1.0-4.0) 
 
3 (2.0-4.0) 
 
% 
  
 
Sex (Males) 
 
72 
 
70 
 
60 
 
Smoking at recruitment 30 
 
27 
 
32 
 
GOLD (stages 1&2) 45 
 
43 
 
55 
 
GOLD (stages 3 & 4)  55 
 
57 
 
42 
 
Attended PR  60 
 
64 
 
62 
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Changes in activity at exacerbation 
 
Figure 33A shows that the mean duration of energy expenditure above 2.5 METs was greater 
during week 1 [(2.18 hours/day (SEM 0.23)) than during week 2(1.98 hours/day (SEM 0.22)); 
p=0.009, n=46]. Time spent lying down either sleeping or resting was not significantly different 
in week 1 (10.93 hours/day (SEM 0.24)) compared to week 2 (11.35 hours/day (SEM 0.26)); 
p=0.158, n=46 (Figure 33B).  Four patients did not complete week 2.  
 
Figure 33C shows that prior to the exacerbation (baseline), the median 6MWD was  422 m 
(IQR 335-502) but fell to 373 m (IQR 262-450) by day 3; p=0.001, paired (n=35).  
Improvements in 6MWD were seen between day 3 and day 7, rising in paired data from 373 
m (262-450) to 415 m (285-480); p<0.001; n=33, but 6MWD was still below baseline on day 
14, 422 m (335-502) compared to baseline values that had a median of 435 m (285-480) 
respectively; p=0.021, n=33. 
  
Changes in QMVC at exacerbation 
 
QMVC mean was 32.6 kg (SEM ±2.7) at baseline but fell to 29.7 kg (±2.5) by day 3; p=0.026, 
paired (n=29). Also, QMVC was still less than baseline on day 7, 29.1 kg (±2.8) compared 
with 32.2 kg (±2.7); p=0.019; n=29. However, by day 14, QMVC had returned to baseline 
levels, 32.7 kg (±2.0) compared to 32.6 kg (±2.1) respectively; p=0.931; n=40 (Figure 33D).  
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Changes in fatigue and depression at exacerbation 
 
Fatigue levels were worse at exacerbation presentation (day 0) compared to the baseline, 31 
(SEM ±1.7) vs. 36 (±1.5); p<0.001; n=39 and on day 3, 35 (±1.5) compared with 37 (±1.4); 
p=0.037; n=36. Depression levels also were higher on day 0 compared to baseline 5 (IQR 2-
7) compared with 4 (2-6); p=0.024, n=31 but had returned to pre-exacerbation levels by day 
3, 4 (2-7) compared with day 0, 4 (2-6); p=0.316; n=28.  
 
Changes in systemic inflammation at exacerbation 
 
Systemic inflammation also rose at exacerbation with CRP increasing from 3.0 mg/l (IQR 1.0-
8.5) at baseline to 8.0 (3.0–37.0) mg/l (p<0.001, n=42 at exacerbation presentation (day 0). It 
remained elevated relative to baseline on day 3 [5.0 (2.0–13.5) mg/l vs 3.0 (1.0-8.5) mg/l; 
p<0.027, n=34] but had fallen significantly from peak levels on day 0 to day 7, [47 (8.0-
37.0)mg/l to 3.0 (1.0-7.0) mg/l; p<0.001, n=43] (Normal CRP range between 0-10 mg/l).  
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Figure 33: A) Duration of light activity in week 1 and week 2 post-exacerbation. B) Duration 
of time in bed at night and sleep or lying down during the day C) 6MWD at baseline and 
during exacerbation recovery. D) Maximal voluntary quadriceps contraction at baseline and 
during exacerbation recovery. Bars for exercise duration (A), time in bed and lying down (B) 
and quadriceps strength (D) are SE, and inter-quartile ranges for 6MWD (C). 
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Determinants of changes in physical activity 
 
Frequent vs. infrequent exacerbators 
I found that patients with infrequent exacerbations (≤2 per year) had a smaller reduction in the 
duration of light activity compared to patients with frequent exacerbations (0.10 hours/day 
(SEM 0.09)) vs (0.40 (0.11)) hours/day respectively; p=0.048, n= 46 (Figure 34A). There were 
no differences between frequent and infrequent exacerbators in the change in 6MWD or 
quadriceps strength between baseline and day 3 (Figure 34B, 34C). 
 
Disease severity 
There were no differences in light energy expenditure or quadriceps strength between 
mild/moderate GOLD stages and severe/very severe GOLD stages.  However, the reduction 
in 6MWD between baseline and day 0 was significantly greater in patients with severe/very 
severe disease compared to mild/moderate GOLD stage patients. -81.2 m (SEM 21.9) vs -
24.1 m (13.8) respectively; [p=0.034] (Figure 34E).  
 
Pulmonary rehabilitation attendance 
Patients who had attended PR had a smaller fall (week 2 – week 1) in the daily duration of 
light activity of only -0.06 hours/day (SEM 0.07) compared to patients who had never 
undertaken PR whose activity fell by -0.41 (0.12) hours/day; p=0.016 (Figure 34G). Similarly, 
there was a smaller change in 6MWD in patients who had attended PR compared to those 
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who had not undertaken PR, -35.0 m (14.1) and -114.9 m (32.2) respectively;  [p=0.013] 
(Figure 34H). There was also a smaller fall in quadriceps muscles strength compared to 
patients who had attended PR [-1.5 kg (1.5) and -6.8 kg (1.4); p=0.055] (Figure 34C).  
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Figure 34: Decrease in light activity duration, 6MWD and quadriceps muscles at 
exacerbation relative to baseline values according to previous history of frequent versus 
infrequent exacerbations (A-C), COPD GOLD grade severity (D-F) and if subject has never or 
ever previously attended a pulmonary rehabilitation course (G-I) 
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Relationship between changes in daily activity fatigue and exercise capacity  
Increasing levels of fatigue (a fall in FACIT-F score) were associated with a greater reduction 
in 6MWD between baseline and day 3 [Figure 35A; r=0.435; p=0.013]. This questionnaire had 
two questions about daily activity and I showed correlations between FACIT-F score and 
6MWT. Removing individual questions on physical activity will affect the questionnaire validity 
and therefore there is the possibility of confounding between the two measures. Figure 35B 
Higher depression scores were associated with larger falls in light energy expenditure 
between the first week and second week [rho=-0.507; p=0.006; n=28]. There was no 
relationship between changes in the duration of light energy expenditure and changes in 
fatigue [r=0.15; p=0.441].  
 
 
Figure 35: Changes in fatigue and 6MWD between baseline and day 3 post-exacerbation 
and B) changes in depression and light activity duration.  
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Changes in systemic inflammation and exercise capacity at exacerbation  
Larger falls in 6MWD between baseline and day 3 were seen in patients with the greatest 
rises in CRP, r=-0.364; p=0.041; n=32 (Figure 36A). Patients with high CRP levels at 
exacerbation presentation had larger falls in 6MWD between day 3 and baseline [r=-0.390; 
p=0.023; n=34] (Figure 36B).  
 
 
Figure 36: The CRP changes and relationship to 6MWD at A) day 3 visit, and B) 
exacerbation presentation visit 
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Patients with a CRP above the group median (>2.55 mg/dl) on the day of exacerbation 
presentation had a significant lower duration of light activity at the first week post 
exacerbation than those below ((mean ± sem) 1.63 ±0.26 vs 2.69 ±0.37 hour/day 
respectively; p=0.026) Figure 37. 
 
 
Figure 37: The difference in light activity duration between patients with low vs high changes 
in CRP level (≤2.55 vs >2.55 mg/dl) from baseline to exacerbation presentation visit (day 0). 
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7.5 DISCUSSION 
 
 
This study showed that exercise capacity, muscle strength and time spent in “light” activity 
with energy expenditure (>2.5 METS) is reduced during community treated exacerbations of 
COPD. Also, for the first time, observed reduction in exercise capacity at exacerbation was 
associated with an increase in systemic inflammation (CRP) levels and related to changes in 
the perception of fatigue. Indeed, I found that changes in the duration of “light” energy 
expenditure during exacerbation recovery were related to increases in depression levels.  An 
additional finding was that patients who had attended pulmonary rehabilitation had a smaller 
decrease at exacerbation in exercise capacity and light activity.   
 
Skeletal muscle dysfunction and wasting is one of the most important extra-pulmonary 
manifestations of COPD. Much of the evidence concerning a possible link between systemic 
inflammation and reduced physical activity is based on statistical associations in cross-
sectional studies which may have been confounded by disease severity and exacerbation 
frequency (261-263).  Evidence from patients hospitalized for an acute exacerbation can be 
difficult to interpret as bed-rest in healthy people will also decrease exercise capacity (264, 
265).  My study examined moderate exacerbations during which patients were at liberty to 
engage in their normal daily activities. This category of exacerbation comprises the majority of 
events that involve health-care resources. My objective was therefore to examine changes in 
physical activity and systemic inflammation before and after a moderate exacerbation.  
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This study showed   a significant association between the rise in CRP at exacerbation and the 
decrease in 6MWD between baseline and 3 days post-presentation. CRP may not have a 
direct effect on muscle but its rise at exacerbation will be correlated with increases in other 
acute-phase proteins such as interleukin-1β, tumor necrosis factor (TNF)-α and α1-
antichymotrypsin (ACP). Chronic treatment with TNF-α or IL-1 in rats decreases muscle 
protein content (266) possibly through interference with myoblast differentiation (267) and 
high levels of ACP are associated with loss of hand grip strength (268). Sputum levels of 
TNF-α and serum levels of ACP increase at exacerbation (269, 270).  
 
Increased systemic inflammation at exacerbation is unlikely to be solely responsible for 
reduced physical activity during these events, especially given that the rises in CRP were 
modest, although it is known that viraemia is associated with transient myalgia and 
measurable respiratory muscle weakness (84). I observed that falls in exercise capacity at 
exacerbation were larger in severe/very severe GOLD grade COPD patients. In healthy 
individuals, muscle fatigue limits exercise capacity but in COPD patients breathlessness may 
cause patients to stop exercising before fatigue is noticeable (150). The role of 
breathlessness is supported by studies which show physical activity related to lung hyper-
inflation (271) which is an important determinant of breathlessness. I observed a 5 unit 
increase in fatigue with exacerbation which is consistent, but smaller, than the 8.3 unit 
increase previously reported (217). One explanation for this inconsistency is that patients 
volunteering to undergo exercise testing at exacerbation may not experience large increases 
in fatigue.  
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In this study, frequent exacerbations were a patient phenotype associated with a greater 
reduction at exacerbation in the duration of light energy expenditure. Donaldson et al 
previously reported that patients with frequent exacerbations experience a significantly faster 
decline in both the amount of time they spend outside the home (3). Thus, this group of 
patients appears at greatest risk of exercise impairment. Patients with frequent exacerbations 
have higher modified Medical Research Council dyspnoea scores (70) and thus may be more 
likely to experience levels of exacerbation-related breathlessness that are sufficient to limit 
activity. Also in this study observed that increases in depression scores between week 2 and 
week 1 correlated with reduced energy expenditure in week 2 compared to week 1.  Higher 
depression scores are seen in patients who spend less time outdoors (160).   
 
In those patients who had attended at some time a course of pulmonary rehabilitation, 
reductions at exacerbation in the duration of “light” energy expenditure and 6MWD were 
significantly smaller than those who had not attended a course.  The effect on QMVC was not 
significant (p=0.055) but the direction and consistency with all three different outcome 
measures was noteworthy. During pulmonary rehabilitation, patients are educated about their 
disease and undergo exercise training to improve muscle strength and desensitize 
themselves to dyspnoea (272, 273).  I believe this is the first time shown that changes in 
patients physical activity at exacerbation related positively to pulmonary rehabilitation and it is 
worthy of prospective investigation as this finding may encourage patient to undertake 
programs.   
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A limitation of the study is that I did not include COPD patients using ambulatory oxygen or 
walking supports, and my results should not be extrapolated to these patient groups. It was 
difficult sometimes to persuade patients with an exacerbation to undertake exertional activity 
and thus data were missing at various time points. Eaton and colleagues have also noticed 
this reluctance to engage in exercise at exacerbation with only 97 of 228 (42%) eligible 
patients agreed to participate in a randomized, controlled trial of early pulmonary 
rehabilitation at exacerbation (274).  I cannot rule out bias because patients who refused to 
be tested may have been the more disabled patients and thus my data may have under-
estimated the true effect. Another limitation is that it was not feasible with a limited number of 
SenseWear devices to prospectively collect stable data over 7 days and to ask the patient to 
make as a special journey to return the device.  
 
This study showed that a high CRP at exacerbation presentation was associated with 
reduced exercise capacity (6MWD).  This might prove to be a useful indicator of those 
patients who should be targeted at exacerbation for extra encouragement to keep active 
whilst suffering an exacerbation and receiving treatment at home.  
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7.6 CONCLUSIONS 
 
In summary, my findings suggest that a greater rise in systemic inflammation at exacerbation 
is associated with a larger reduction in exercise capacity which is associated with increases in 
symptoms of depression and fatigue.  Decreases in exercise capacity and physical activity at 
exacerbation are greater in those with more severe disease and those with a history of 
frequent exacerbations.  It is possible that prior pulmonary rehabilitation may protect against 
loss of exercise capacity and physical activity at exacerbation 
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8 
CONCLUSIONS 
AND 
SUGGESTIONS 
FOR FUTURE 
STUDIES 
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8.1 CONCLUSIONS 
 
 
Each chapter has its own discussion and conclusion, but in general terms, this thesis shows 
that moderate, community-treated exacerbations have a measurable but brief impact on the 
physical activity of COPD patients. This is important as COPD patients will likely experience a 
number of moderate exacerbations before they are hospitalized for a severe exacerbation. 
Thus, the descent into inactivity related to exacerbations starts early in the course of disease 
and activity related interventions should be targeted to begin at an early stage. More research 
into the consequences of inactivity at moderate exacerbations is needed, in addition to 
hospital based studies on COPD patients. 
  
Pulmonary rehabilitation improves exercise tolerance (116), which means that patients should 
be continually encouraged to increase their physical activity. In this study, I observed that 
patients who had undergone pulmonary rehabilitation had a smaller reduction in daily activity 
and quadriceps muscle strength than patients who had not undergone rehabilitation, which 
suggests that it may confer a hitherto unexplored longer-term benefit.   It is also important as 
attempts to encourage activity during the early stages of exacerbation recovery to prevent de-
conditioning have not been successful because of non-participation and early withdrawal.  
  
Pharmacological interventions that hasten exacerbation recovery would be beneficial to 
patients in a number of ways, particularly by reducing symptom burden and extending the 
time to the next event. Such interventions would also allow patients to return to normal activity 
and thus are urgently needed.  
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It was observed that frequent exacerbators have acceleration in the age-related decline in 
daily activity. This group of patients may benefit most from continued exercising and 
pulmonary rehabilitation. This is supported by the finding that they had a greater reduction in 
the duration of light activity compared with patients with infrequent exacerbations. Impairment 
of daily activity may be one of the factors prompting patients to report exacerbations to their 
physician for treatment. The causes of unreported exacerbations are not well understood, and 
their relationship with impairment of daily activity requires further investigation. 
  
During cold and overcast and rainy days, unlike warm, sunny and dry days, inactivity is 
greatest. Indoor exercise classes could be promoted during the wintertime. At the weekends, 
it was observed that the activity of patients was reduced compared with the rest of the week. 
Pulmonary Rehabilitation at the weekend is unlikely to be a priority for the NHS but patients 
could be educated to increase activity at the weekend or at least be warned that this is an 
important time for exercise. I found evidence that COPD patients' daily activity is reduced 
when levels of atmospheric pollution are high. Schemes to reduce the level of atmospheric 
pollution or prevent very high peaks should be put in place so that COPD patients are not 
imprisoned in their homes.  
  
Exacerbations are inflammatory events (4). I observed a relationship between increased 
systemic inflammation and reduced physical activity at exacerbation. The data are not proof 
of causation but do not contradict the hypothesis that reducing inflammation may improve 
physical performance.  
 
Agreement was shown between the steps counted by pedometer and the actual steps 
obtained when a walking test was performed. Pedometry is a simple, affordable and 
  
198 
 
increasingly fashionable method for monitoring daily physical activity. Studies are required to 
test whether giving patients such devices encourages them to exercise more.  
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Main findings 
 
 Simple, cheap pedometers can be used to monitor patients‟ everyday activities during 
exacerbations treated in the community. 
 
 Over a one-month period, average daily step count correlates moderately well with 
objective tests of exercise capacity, and of quadriceps muscle strength. 
 
 
 Moderately severe COPD exacerbation reduced physical activity with patients recovering 
within three-four days.   
 
 Frequent exacerbations accelerate the reduction over time in a patient‟s physical activity.  
 
 
 COPD patient are most inactive during the winter, and pulmonary rehabilitation 
interventions that reduce inactivity could be implemented within this period.  
 
 Physical activity also diminishes during weekends. Patients should therefore be 
encouraged to sustain physical activity on weekends. 
 
 Less physical activity in COPD patients is associated with atmospheric pollution. Public 
health initiatives that seek to minimize air pollution need to be emphasized.  
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 Patients who have had pulmonary rehabilitation classes had smaller reductions in physical 
activity at exacerbation and smaller rises in systemic inflammatory markers. These 
associations should be treated cautiously but merit further investigation. 
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8.2 SUGGESTIONS FOR FUTURE WORK  
 
 
 
1-   COPD patients experience progressive decline in pulmonary function and daily activity 
and get worse acutely at exacerbation. Further work is needed to validate the newer range of 
devices currently available to assess this, such as wristband pedometers. These devices are 
popular with younger members of the public but utility in elderly COPD patients‟ needs to be 
investigated. 
 
  
 
 
 
2-   Chronic obstructive pulmonary disease is characterised by breathlessness and reduced 
daily activity which worsens acutely at exacerbation. In this thesis I showed that prior 
pulmonary rehabilitation within on average two years was associated with less loss of 
exercise capacity and physical activity at exacerbation. It would be worth examining this 
finding in a prospective study in which prior pulmonary rehabilitation attendance in the same 
year of exacerbation is related to the change in physical activity, exercise capacity and 
muscle strength between stable and exacerbation recovery visits. 
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3- The skeletal muscles of patients with COPD have increased expression of TNF, CRP, IL-6 
and other inflammatory cytokines and compared with normal individual. These are factors 
which may contribute to muscle wasting and dysfunction. In previous studies it has been 
shown that inflammation is linked to muscle weakness (145, 261, 262), while others studies 
showed that muscles weakness related to fatigue (275). However, interventional experiments 
are needed to examine the relationship between pro and anti-inflammatory mediators, fatigue 
and physical activity. 
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NAME ____________________________________       DATE   _____/_____/_____ 
 
 
Hospital Anxiety and Depression Scale (HADS) 
 
I feel tense or ‘wound up’:  A   I feel as if I am slowed down:  D  
Most of the time  3   Nearly all of the time  3  
A lot of the time  2   Very often  2  
Time to time, occasionally  1   Sometimes  1  
Not at all  0   Not at all  0  
     
I still enjoy the things I used to enjoy:  D    I get a sort of frightened feeling like 
‘butterflies in the stomach’:  
A  
Definitely as much  0    Not at all  0  
Not quite so much  1    Occasionally  1  
Only a little  2    Quite often  2  
Not at all  3    Very often  3  
     
I get a sort of frightened feeling like 
something awful is about to happen:  
A   I have lost interest in my appearance:  D  
Very definitely and quite badly  3   Definitely  3  
Yes, but not too badly  2   I don‟t take as much care as I should  2  
A little, but it doesn‟t worry me  1   I may not take quite as much care  1  
Not at all  0   I take just as much care as ever  0  
     
I can laugh and see the funny side of things:  D    I feel restless as if I have to be on the 
move:  
A  
As much as I always could  0    Very much indeed  3  
Not quite so much now  1    Quite a lot  2  
Definitely not so much now  2    Not very much  1  
Not at all  3    Not at all  0  
     
Worrying thoughts go through my mind:  A   I look forward with enjoyment to things:  D  
A great deal of the time  3   A much as I ever did  0  
A lot of the time  2   Rather less than I used to  1  
From time to time but not too often  1   Definitely less than I used to  3  
Only occasionally  0   Hardly at all  2  
     
I feel cheerful:  D    I get sudden feelings of panic:  A  
Not at all  3    Very often indeed  3  
Not often  2    Quite often  2  
Sometimes  1    Not very often  1  
Most of the time  0    Not at all  0  
     
I can sit at ease and feel relaxed:  A   I can enjoy a good book or radio or TV 
programme:  
D  
Definitely  0   Often  0  
Usually  1   Sometimes  1  
Not often  2   Not often  2  
Not at all  3   Very seldom  3  
Questions relating to anxiety are indicated by an 'A' while those relating to depression are shown by a 'D'. Scores of 0-7 in respective subscales are considered 
normal, with 8-10 borderline and 11 or over indicating clinical 'caseness' 
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APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LONDON COPD STUDY                 Muscle Assessments 
COPDMAP STUDY 
Name 
 
 Cohort No  Date  
Visit Type A/R  3-month 
Baseline 
 6-month 
Baseline 
 
Exacerbation  Post 
exacerbation 
2W 
 Post 
exacerbation 
6W 
 
Muscle Strength 
Assessment (QMVC) 
done? 
Yes  No  Contra-
indications 
 
Leg (circle) R/L No. 
attempts 
 
Reading 1 Reading 
2 
Reading 
3 
Reading 
4 
Reading 5 Reading 
6 
Best 
 
 
      
  
250 
 
6MWT Worksheet 
Patient name: ____________________      Patient ID# ___________ 
Date:___________________ 
Medications taken before the test (dose and time): __________________ 
_______________________________________________________________ 
Supplemental oxygen during the test: No Yes 
flow ______ L/min, type ___                
 
                                    Pre-Test                 End of Test 
Time                         ___:___                       ___:___ 
  
Heart Rate                _____                            _____ 
 
Dyspnea                    ____                             ____ (Borg scale) 
 
Fatigue                      ____                             ____ (Borg scale) 
 
SpO2                         ____ %                        ____% 
Did the patient complete the six minute walk?  Yes      No 
If No please circle the primary reason the subject did not complete the test 
Breathlessness             chest pain               Dizziness               General fatigue                 
Leg fatigue        Test was contraindicated per ATS guideline   
Other , Please specify 
Number of laps: ______(X60meters)+ final partial lap:______ meters 
    =Total distance walked in 6 minutes:________meters_____________             
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